

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 902 035 A2

(12) **EUROPEAN PATENT APPLICATION**(43) Date of publication:
17.03.1999 Bulletin 1999/11(51) Int. Cl.⁶: C07K 14/32, C12N 9/00,
C12N 15/11, C12N 15/31

(21) Application number: 98116786.9

(22) Date of filing: 05.09.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI


- Kalman, Lisa Vivian
San Francisco, California 94131 (US)
- Myers, Thomas W.
Alameda, California (US)
- Reichert, Fred Lawrence
Oakland, California 94610 (US)
- Sigua, Christopher Lim
Antioch, California (US)

(30) Priority: 11.09.1997 US 58525 P

(71) Applicant:
F. HOFFMANN-LA ROCHE AG
4070 Basel (CH)(74) Representative:
Wächter, Dieter Ernst, Dr. et al.
F.Hoffmann-La Roche AG
Patent Department (PLP),
124 Grenzacherstrasse
4070 Basel (CH)(72) Inventors:
• Gelfand, David H.
Oakland, California 94611 (US)(54) **Altered thermostable DNA polymerases for sequencing**

(57) Modified thermostable DNA polymerases having enhanced efficiency for incorporating unconventional nucleotides such as those labeled with fluorescein family dyes are provided. Such modified thermostable DNA polymerases can be prepared by methods of the recombinant DNA technology. Recombinant thermostable DNA polymerases prepared in accordance with the present invention are advantageous in many in vitro DNA synthesis applications, such as DNA sequencing, synthesis of labeled DNA and the production of labeled primer extension products. The said polymerase enzymes are particularly useful in chain termination nucleic acid sequencing methods. Nucleic acids encoding the recombinant thermostable DNA polymerases of the present invention, as well as vectors and host cells comprising same are also provided. Kits comprising the recombinant thermostable DNA polymerases of the present invention are provided too. The polymerases and methods of the present invention provide significant cost and efficiency advantages for DNA sequencing.

Fig. 1



Description

Field of the Invention

5 [0001] The present invention relates to thermostable DNA polymerases which have enhanced efficiency for incorporating nucleoside triphosphates labeled with fluorescein family dyes. The present invention provides means for isolating and producing such altered polymerases. The enzymes of the invention are useful for many applications in molecular biology and are particularly advantageous for nucleic acid sequencing.

10 Background of the Invention

[0002] Incorporation of nucleoside triphosphates (dNTPs) labeled with fluorescent dyes is important for many *in vitro* DNA synthesis applications. For example, dye-terminator DNA sequencing reactions require the incorporation of fluorescent dideoxynucleotide analogues for termination and labeling. In addition, *in vitro* synthesis of labeled products may involve incorporation of fluorescent nucleotides or nucleotide analogues. For example, fluorescently labeled DNA has been used in hybridization assays using microarrays of immobilized probes (Cronin *et al.*, 1996, Human Mutation 7:244).

[0003] To assure fidelity of DNA replication, DNA polymerases have a very strong bias for incorporation of their normal substrates, referred to herein as conventional deoxynucleoside triphosphates (dNTPs), and against incorporation of unconventional dNTPs including dNTPs and dNTP analogues labeled with fluorescent dyes. In the cell, this property attenuates the incorporation of abnormal bases such as dUTP in a growing DNA strand. *In vitro*, this characteristic is particularly evident where both conventional and unconventional fluorescently-labeled nucleoside triphosphates are present, such as in DNA sequencing reactions using a version of the dideoxy chain termination method that utilizes dye-terminators (Lee *et al.*, 1992, Nuc. Acids. Res. 20:2471 which is incorporated herein by reference).

25 [0004] Commercially available DNA cycle sequencing kits for dye-terminator methods use chain terminator ddNTPs labeled with fluorescent dyes of the rhodamine family. However, rhodamine dyes are zwitterionic in charge and nucleoside triphosphates labeled with these dyes migrate anomalously in the electrophoretic gels used to separate the sequencing products for detection. This property of rhodamine family dyes necessitates making modifications in the standard sequencing protocol which include the use of dITP and an additional processing step before electrophoresis.

30 [0005] In contrast, negatively charged fluorescent dyes such as fluorescein family dyes allow 1) better separation between the labeled nucleoside triphosphates and labeled primer extension products, and 2) better electrophoretic migration of the labeled sequencing products than neutral or positively charged fluorescent dyes. Thus, the use of fluorescein family dyes avoids the need for additional processing steps required with the use of rhodamine family dyes. However, available dyes of the fluorescein family are not ideal for use in current commercially available DNA cycle sequencing formats because ddNTPs labeled with these dyes are not efficiently incorporated into sequencing products using these formats. Consequently, there is a need for commercially available thermostable DNA polymerases that can efficiently incorporate both conventional and fluorescein-labeled nucleotides. The present invention serves to meet that need. Further, an unexpected property of the mutant enzymes of this invention is the increased rate of primer extension relative to the corresponding wild-type enzyme. Another unexpected property is the increased uniformity of incorporation of the various terminator nucleotides in automated DNA sequence analysis.

Summary of the Invention

45 [0006] The present invention provides template-dependent thermostable DNA polymerase enzymes having reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes compared to previously characterized enzymes. These enzymes incorporate nucleotides, including deoxynucleotides (dNTPs) and base analogues such as dideoxynucleotides (ddNTPs), that are labeled with fluorescein family dyes more efficiently than conventional thermostable enzymes. Genes encoding these enzymes are also provided by the present invention, as are recombinant expression vectors for providing large amounts of purified enzymes.

50 [0007] By the present invention, a region of criticality within thermostable DNA polymerases is identified which affects the polymerase's ability to incorporate nucleotides labeled with fluorescein family dyes, while retaining the ability to incorporate faithfully natural nucleotides. This region of criticality, or Critical Motif, can be introduced into genes for thermostable DNA polymerases by recombinant DNA methods such as site-specific mutagenesis to provide the advantages of the invention.

55 [0008] Thus, in one aspect, the invention provides recombinant thermostable DNA polymerase enzymes which are characterized in that the enzymes have been mutated to produce the Critical Motif and have reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes, in comparison to the corresponding wild-type enzyme.

[0009] In this aspect, the invention provides recombinant thermostable DNA polymerase enzymes which are characterized in that a) in its native form said polymerase comprises the amino acid sequence (given in one-letter code) LSXXLX(V/I)PXXE (SEQ ID NO: 1), where X is any amino acid; b) the X at position 4 in said sequence is mutated in comparison to said native sequence, except that X is not mutated to E; and c) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison to the native form of said enzyme. In the three-letter code, this amino acid sequence is represented as LeuSerXaaXaaLeuXaaXaaProXaaXaaGlu (SEQ ID NO: 1), whereby "Xaa" at positions 3, 4, 6, 9, and 10 of this sequence are any amino acid residue, and "Xaa" at position 7 of this sequence is Val or Ile.

[0010] In another embodiment, the recombinant thermostable DNA polymerases are characterized in that a) the native form of the polymerase comprises the amino acid sequence LS(Q/G)XL(S/A)IPYEE (SEQ ID NO: 2), where X is any amino acid; b) the X at position 4 in said sequence is mutated in comparison to said native sequence, except that X is not mutated to E; and c) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison to the native form of said enzyme. In the three-letter code, this amino acid sequence is represented as LeuSerXaaXaaLeuXaalleProTyrGluGlu (SEQ ID NO: 2), whereby "Xaa" at position 3 is Gln or Gly, "Xaa" at position 4 is any amino acid, and "Xaa" at position 6 is Ser or Ala. In a preferred embodiment, the amino acid sequence is LSQXLAIPYEE (SEQ ID NO: 3), where X is any amino acid. In the three-letter code, this amino acid sequence is represented as LeuSerGlnXaaLeuAlalleProTyrGluGlu (SEQ ID NO: 3), whereby "Xaa" at position 4 is any amino acid. In a more preferred embodiment, the "Xaa" at position 4 is Lys.

[0011] In yet another embodiment, the recombinant thermostable DNA polymerases are characterized in that a) the native form of the polymerase comprises the amino acid sequence LSVXLG(V/I)PVKE (SEQ ID NO: 4); b) the X at position 4 in said sequence is mutated in comparison to said native sequence, except that X is not mutated to E; and c) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison to the native form of said enzyme. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyXaaProValLysGlu (SEQ ID NO: 4), whereby "Xaa" at position 4 is any amino acid and "Xaa" at position 7 is Val or Ile. In a preferred embodiment, the amino acid sequence is LSVXLGVPVKE (SEQ ID NO: 5) where X at position 4 is any amino acid. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyValProValLysGlu (SEQ ID NO: 5), whereby "Xaa" at position 4 is any amino acid. In a more preferred embodiment, the "Xaa" at position 4 is Arg. In another preferred embodiment, the amino acid sequence is LSVXLGIPVKE (SEQ ID NO: 6) where X at position 4 is any amino acid. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlylleProValLysGlu (SEQ ID NO: 6), whereby "Xaa" at position 4 is any amino acid. In a more preferred embodiment, the "Xaa" at position 4 is Arg.

[0012] In another aspect of this invention, the particular region of criticality of this invention can be combined with motifs in other regions of the polymerase gene that are known to provide thermostable DNA polymerases with reduced discrimination against incorporation of unconventional nucleotides such as rNTPs and ddNTPs. As exemplified herein, a recombinant *Thermus aquaticus* (*Taq*) DNA polymerase enzyme containing two mutations was constructed. The first mutation was an E to K mutation in the X residue at position 4 of the critical motif of this invention. The second mutation was a mutation allowing more efficient incorporation of ddNTPs known as the F667Y mutation. This mutation is a phenylalanine to tyrosine mutation at position 667 of *Taq* DNA polymerase (described in U.S. Patent No 5,614,365 and U.S. Serial No 8/448,223 and herein incorporated by reference). When used in a sequencing reaction with fluorescein dye family-labeled ddNTPs, the E681K F667Y double mutant enzyme was found to produce a readable sequencing ladder. Thus, in one embodiment, a motif conferring reduced discrimination toward dideoxynucleotides is combined with the critical motif of this invention to provide an enzyme having an increased efficiency of incorporation of both labeled and unlabeled ddNTPs.

[0013] In addition, the E681K F667Y mutant enzyme was unexpectedly found to exhibit a significantly increased extension rate relative to an enzyme with the F667Y mutation alone. Thus, in another embodiment of the invention, introduction of the critical motif into a thermostable DNA polymerase enzyme, alone or in combination with other motifs, produces enzymes having an increased extension rate. The double mutant enzyme was also unexpectedly found to produce more uniform peak heights in dye-terminator dideoxy sequencing using rhodamine-labeled terminators. Thus, in yet another embodiment, introduction of the critical motif into a thermostable DNA polymerase enzyme produces enzymes displaying more uniform peak heights in DNA sequencing methods using rhodamine dye family labeled terminators.

[0014] In another embodiment, a mutation allowing more efficient incorporation of rNTPs, such as the glutamic acid to glycine mutation at position 615 of *Taq* DNA polymerase, or E615G mutation (described in European Patent Application, Publication No. EP-A-823 479, herein incorporated by reference), is combined with the critical motif of this invention to provide an enzyme having an increased efficiency of incorporation of ribonucleotides labeled with fluorescein family dyes.

[0015] In another aspect of this invention, genes encoding the polymerases of this invention are also provided. Specifically, genes encoding recombinant thermostable polymerases comprising the critical motif of this invention are pro-

vided. Also included in this aspect are genes encoding combinations of two or more mutations that include mutations producing the critical motif of this invention.

[0016] In yet another aspect, the invention also provides improved methods of DNA sequencing that allow the use of lower concentrations of fluorescein dye family-labeled ddNTPs, thereby reducing the cost of performing the reactions. The improved methods of the invention also allow the use of lower ratios of fluorescein dye family-labeled ddNTPs to dNTPs. Use of these methods results in numerous advantages, including more efficient polymerization, lower concentrations of template nucleic acid being required, and a decreased likelihood of introducing inhibitors into the reaction mix. These advantages also facilitate the sequencing of long templates. The invention also provides improved methods of sequencing wherein sequencing reactions can be loaded directly onto sequencing gels for subsequent electrophoresis without intermediate purification.

[0017] Thus, in one embodiment of the invention, the invention provides improved methods for determining the sequence of a target nucleic acid using a recombinant enzyme which has a) a mutation at position 4 which produces the critical motif of this invention and b) has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison with the corresponding wild-type enzyme. Also within the scope of this invention are improved sequencing methods using thermostable DNA polymerase enzymes derived from thermophilic species, where the enzymes contain naturally occurring sequence variations that produce the critical motif of this invention. These native enzymes can also provide reduced discrimination against incorporation of unconventional nucleotides. In this embodiment, the invention provides improved methods of sequencing using a native thermostable DNA polymerase a) having the critical motif of this invention wherein the amino acid in position 4 is not Glu and b) having reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes.

[0018] Also within the scope of this invention are improved methods of producing DNA labeled with fluorescein family dyes. The enzymes of the invention efficiently incorporate fluorescein-labeled dNTPs in a polymerase chain reaction method, producing amplified products that are labeled at various sites with fluorescein family dyes. Thus, in one embodiment, an improved method of labeling DNA comprises a) providing a reaction mixture comprising dNTPs labeled with fluorescein family dyes and an enzyme of the invention and b) performing a nucleic acid amplification reaction.

[0019] The enzymes of the invention, and genes encoding these enzymes, provide additional aspects of the invention which are kits for DNA sequencing that comprise a recombinant enzyme of the invention and may additionally include a negatively charged fluorescent terminator compound. Other kits for DNA sequencing comprise a) a negatively charged fluorescent terminator compound and b) a native enzyme of the invention.

[0020] The invention also provides kits for producing labeled DNA which comprise a recombinant enzyme of the invention. Other kits for producing labeled DNA comprise a) a negatively charged fluorescent nucleoside triphosphate compound and b) a native enzyme of the invention.

Brief Description of the Drawing

[0021]

Figure 1 is a schematic representation of the *Taq* DNA polymerase gene. Restriction sites are indicated that relate to Example I and the description of methods for preparing additional mutants and expression vectors provided herein.

Detailed Description of the Invention

[0022] To facilitate understanding of the invention, a number of terms are defined below.

[0023] The term "gene" refers to a DNA sequence that comprises control and coding sequences necessary for the production of a recoverable bioactive polypeptide or precursor. The polypeptide can be encoded by a full-length gene sequence or by any portion of the coding sequence so long as the enzymatic activity is retained.

[0024] The term "native" refers to a gene or gene product which is isolated from a naturally occurring source. This term also refers to a recombinant form of the native protein produced by molecular biological techniques which has an amino acid sequence identical to that of the native form.

[0025] The term "mutant" refers to a gene that has been altered in its nucleic acid sequence or a gene product which has been altered in its amino acid sequence, resulting in a gene product which may have altered functional properties when compared to the native or wild-type gene or gene product. Such alterations include point mutations, deletions and insertions.

[0026] The term "host cell(s)" refers to both single-cellular prokaryote and eukaryote organisms such as bacteria, yeast, and actinomycetes and single cells from higher order plants or animals when being grown in cell culture.

[0027] The term "expression system" refers to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that host cells transformed with these sequences are capable of producing the

encoded proteins. To effect transformation, the expression system may be included on a vector; however, the relevant DNA may also be integrated into the host chromosome.

[0028] The term "oligonucleotide" as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size of an oligonucleotide will depend on many factors, including the ultimate function or use of the oligonucleotide.

[0029] Oligonucleotides can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphotriester method of Narang *et al.*, 1979, *Meth. Enzymol.* 68:90-99; the phosphodiester method of Brown *et al.*, 1979, *Meth. Enzymol.* 68:109-151; the diethylphosphoramidite method of Beaucage *et al.*, 1981, *Tetrahedron Lett.* 22: 1859-1862; the triester method of Matteucci *et al.*, 1981 *J. Am. Chem. Soc.* 103:3185-3191 or automated synthesis methods; and the solid support method of U.S. Patent No. 4,458,066, which publications are each incorporated herein by reference.

[0030] The term "primer" as used herein refers to an oligonucleotide, whether natural or synthetic, which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. A primer is preferably a single-stranded oligodeoxyribonucleotide. The appropriate length of a primer depends on the intended use of the primer but typically ranges from 15 to 35 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template but must be sufficiently complementary to hybridize with a template for primer elongation to occur.

[0031] A primer can be labeled, if desired, by incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include ^{32}P , fluorescent dyes, electron-dense reagents, enzymes (as commonly used in ELISA assays), biotin, or haptens and proteins for which antisera or monoclonal antibodies are available.

[0032] The term "thermostable polymerase," refers to an enzyme which is stable to heat, is heat resistant and retains sufficient activity to effect subsequent primer extension reactions and does not become irreversibly denatured (inactivated) when subjected to the elevated temperatures for the time necessary to effect denaturation of double-stranded nucleic acids. The heating conditions necessary for nucleic acid denaturation are well known in the art and are exemplified in U.S. Patent Nos. 4,683,202 and 4,683,195, which are incorporated herein by reference. As used herein, a thermostable polymerase is suitable for use in a temperature cycling reaction such as the polymerase chain reaction ("PCR"). Irreversible denaturation for purposes herein refers to permanent and complete loss of enzymatic activity. For a thermostable polymerase, enzymatic activity refers to the catalysis of the combination of the nucleotides in the proper manner to form primer extension products that are complementary to a template nucleic acid strand.

[0033] The term "conventional" or "natural" when referring to nucleic acid bases, nucleoside triphosphates, or nucleotides refers to those which occur naturally in the polynucleotide being described (i.e., for DNA these are dATP, dGTP, dCTP and dTTP). Additionally, dTTP, and 7-deaza-dGTP are frequently utilized in place of dGTP and 7-deaza-dATP can be utilized in place of dATP in *in vitro* DNA synthesis reactions, such as sequencing. Collectively these may be referred to as dNTPs.

[0034] The term "unconventional" or "modified" when referring to a nucleic acid base, nucleoside, or nucleotide includes modification, derivations, or analogues of conventional bases, nucleosides, or nucleotides that naturally occur in a particular polynucleotide. The deoxyribonucleotide form of uracil is an unconventional or modified base in DNA (dUMP), whereas, the ribonucleotide form of uracil is a conventional base in RNA (UMP). As used herein, unconventional nucleotides include but are not limited to compounds used as terminators for nucleic acid sequencing. Terminator compounds include but are not limited to those compounds which have a 2',3' dideoxy structure and are referred to as dideoxynucleoside triphosphates. The dideoxynucleoside triphosphates ddATP, ddTTP, ddCTP and ddGTP are referred to collectively as ddNTPs. Other unconventional nucleotides include phosphorothioate dNTPs ($[\alpha\text{-S}]$ dNTPs), 5'- α -borano-dNTPs, α -methyl-phosphonate dNTPs, and ribonucleoside triphosphates (rNTPs). Unconventional bases may be labeled with radioactive isotopes such as ^{32}P , ^{33}P , or ^{35}S ; fluorescent labels; chemiluminescent labels; bioluminescent labels; hapten labels such as biotin; or enzyme labels such as streptavidin or avidin. Fluorescent labels may include dyes that are negatively charged, such as dyes of the fluorescein family, or dyes that are neutral in charge, such as dyes of the rhodamine family, or dyes that are positively charged, such as dyes of the cyanine family. Dyes of the fluorescein family include e.g., FAM, HEX, TET, JOE, NAN and ZOE. Dyes of the rhodamine family include Texas Red, ROX, R110, R6G, and TAMRA. FAM, HEX, TET, JOE, NAN, ZOE, ROX, R110, R6G, and TAMRA are marketed by Perkin-Elmer (Foster City, CA), and Texas Red is marketed by Molecular Probes. Dyes of the cyanine family include Cy2, Cy3, Cy5, and Cy7 and are marketed by Amersham (Amersham Place, Little Chalfont, Buckinghamshire, England).

[0035] The term "DNA synthesis reaction" refers to methods of producing copies of DNA including but not limited to PCR, strand displacement amplification, transcription mediated amplification, primer extension and reverse transcription.

[0036] In order to further facilitate understanding of the invention, specific thermostable DNA polymerase enzymes and fluorescent dyes are referred to throughout the specification to exemplify the invention, and these references are

not intended to limit the scope of the invention.

[0037] The present invention provides novel and improved compositions which are thermostable DNA polymerases. The enzymes of the invention include recombinant polymerases which more efficiently incorporate nucleoside triphosphates labeled with fluorescein family dyes in comparison to the corresponding wild-type enzymes. The thermostable DNA polymerases of the invention are more suitable and desirable for use in processes such as DNA sequencing and *in vitro* synthesis of labeled products than prior art polymerases. Improved DNA sequencing methods of the invention include the use of these recombinant polymerases as well as the use of native enzymes which more efficiently incorporate nucleoside triphosphates labeled with fluorescein family dyes than previously characterized enzymes. DNA sequences encoding these enzymes, and vectors for expressing the proteins are also provided.

[0038] The thermostable DNA polymerases of the invention possess a region of criticality within the amino acid sequence of the polymerase activity domain of the enzyme. The critical region within the amino acid sequence of a thermostable DNA polymerase provided by the present invention is shown below using the conventional single-letter amino acid code (Lehninger, Biochemistry, New York, New York, Worth Publishers Inc., 1970, page 67, which is incorporated herein by reference).

SEQ ID NO: 7 LSXXLX(V/I)PXXE where the "X" at position 4 indicates any amino acid except E. In the three-letter code for amino acids, this sequence is represented as LeuSerXaaXaaLeuXaaXaaProXaaXaaGlu (SEQ ID NO: 7) whereby "Xaa" at positions 3, 6, 9, and 10 is any amino acid, "Xaa" at position 4 of this sequence is any amino acid but not a glutamic acid residue (Glu) and "Xaa" at position 7 is Val or Ile. This region of criticality provides thermostable DNA polymerase enzymes characterized by the ability to efficiently incorporate nucleotides labeled with fluorescein family dyes.

[0039] For example, in a derivative of the *Thermus aquaticus* (*Taq*) DNA polymerase gene which already contains a glycine to aspartic acid mutation at position 46 (G46D) and an F667Y mutation, a mutation of G to A in the first position of the codon for glutamic acid at residue 681 sequence of the full length *Taq* DNA polymerase sequence (corresponding to position 4 of the critical motif) results in an enzyme having the critical motif. This enzyme displays 1) an approximately a 2- to 10-fold increase in the efficiency of incorporation of nucleotides labeled with fluorescein family dyes with no impairment of the enzyme's ability to mediate PCR in the presence of conventional nucleotides and 2) a 3 to 4.3-fold increase in the extension rate. In *Taq* DNA polymerase this particular mutation results in an amino acid change of E (glutamic acid) to K (lysine).

[0040] Although this particular amino acid change produced the critical motif and significantly alters the ability of the enzyme to incorporate unconventional nucleotides, it is expected that the specific change of E to K is not as critical to the invention as is the now identified position within the region of criticality. Thus, in a preferred embodiment, the invention provides recombinant thermostable DNA polymerase enzymes which are characterized in that a) in its native form said polymerase comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1), where X is any amino acid; b) the X at position 4 in said sequence is mutated in comparison to said native sequence, except that the X at position 4 is not mutated to E; and c) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison to the native form of said enzyme. In a more preferred embodiment, the X at position 4 is replaced by an amino acid having a positive charge, such as K, R or H, or by a polar amino acid such as Q or N. In a most preferred embodiment, the X at position 4 is replaced by K.

[0041] In another preferred embodiment of the invention, the of the invention is characterized in that the enzyme (a) has reduced discrimination against fluorescein dye family labeled nucleotides and (b) comprises the amino acid sequence LS(Q/G)XL(S/A)IPYEE where X is any amino acid (SEQ ID NO: 2). In three-letter code, this amino acid sequence is represented as follows: LeuSerXaaXaaLeuXaaIleProTyrGluGlu, whereby "Xaa" at position 3 is Gln or Gly, "Xaa" at position 4 is any amino acid, and "Xaa" at position 6 is Ser or Ala.

[0042] In a more preferred embodiment of the invention, the enzyme having reduced discrimination against fluorescein dye family labeled nucleotides comprises the amino acid sequence LSQXLAIPYEE where X is any amino acid (SEQ ID NO: 3). In the three-letter code, this amino acid sequence is represented as LeuSerGlnXaaLeuAlaIleProTyrGluGlu, whereby "Xaa" at position 4 is any amino acid. In a most preferred embodiment of the invention, the X is a K residue.

[0043] In another preferred embodiment of the invention, the the enzyme having reduced discrimination against fluorescein dye family labeled nucleotides comprises the amino acid sequence LSVXLG(V/I)PVKE where X is any amino acid (SEQ ID NO: 4). In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyXaaProValLysGlu, whereby "Xaa" at position 4 is any amino acid and "Xaa" at position 7 is Val or Ile.

[0044] In a more preferred embodiment of the invention, the enzyme having reduced discrimination against fluorescein dye family labeled nucleotides comprises the amino acid sequence LSVXLGVPVKE where X is any amino acid (SEQ ID NO: 5). In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyValProValLysGlu, whereby "Xaa" at position 4 is any amino acid. In a most preferred embodiment, the X is an R residue.

[0045] In another more preferred embodiment, the enzyme having reduced discrimination against fluorescein dye family labeled nucleotides comprises the amino acid sequence LSVXLGIPVKE where X is any amino acid (SEQ ID NO:

6). In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlylleProValLysGlu, whereby "Xaa" at position 4 is any amino acid. In a most preferred embodiment, the X is an R residue.

[0046] The characterization of the E681K mutation described herein identified a region in the DNA polymerase gene that affects the ability of the polymerase to interact with negatively charged fluorescent nucleotides. This site, distal to helix O₁, is at the end of the O₂ helix and the beginning of the O₃ helix of the polymerase (Kim, *et al.*, 1995, Nature, 376:612). Based on molecular modeling principles well-known in the art, changes in the structure of the O₂-O₃ helix other than E to K at position 681 are also expected to produce changes in the ability of the polymerase to discriminate against nucleotides labeled with fluorescein family dyes. Thus, mutations at positions in the critical motif other than those in the X residue at position 4 are also within the scope of this invention. In this embodiment, the invention provides a recombinant thermostable DNA polymerase enzyme which is characterized in that (a) in its native form, the polymerase comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid, (b) the recombinant polymerase comprises at least one mutation within the amino acid sequence, except that X at position 4 is not mutated to E, and c) the enzyme has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes, in comparison to the corresponding native enzyme.

[0047] Similarly, thermostable DNA polymerases that comprise critical motifs that are similar, but not identical to the critical motif that is amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 7) where X at position 4 is any amino acid except E, are within the scope of this invention. Specifically, in one embodiment, the critical motif is the amino acid sequence LXXXXXXXXE (SEQ ID NO: 8) where X at position 4 is any amino acid except E. In the three letter code, this amino acid sequence is represented as LeuXaaXaaXaaXaaXaaXaaXaaXaaGlu (SEQ ID NO: 8), whereby "Xaa" at positions 2, 3, 5, 6, 7, 8, 9 and 10 are any amino acid and "Xaa" at position 4 is any amino acid except Glu.

[0048] In another embodiment, the critical motif is amino acid sequence L(S/A)XX(L/I)XXXXXE (SEQ ID NO: 9) where X at position 4 is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuXaaXaaXaaXaaXaaXaaXaaXaaGlu (SEQ ID NO: 9), whereby "Xaa" at positions 3, 6, 7, 8, 9, and 10 are any amino acid, "Xaa" at position 2 is Ser or Ala, "Xaa" at position 4 is any amino acid except Glu, and "Xaa" at position 5 is Leu or Ile.

[0049] In yet another embodiment, the critical motif is amino acid sequence LSXXLXXXXXE (SEQ ID NO: 10) where X at position 4 is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerXaaXaaLeuXaaXaaXaaXaaXaaGlu (SEQ ID NO: 10), whereby "Xaa" at positions 3, 6, 7, 8, 9, and 10 are any amino acid and "Xaa" at position 4 is any amino acid except Glu.

[0050] The ability of the enzymes of this invention to efficiently incorporate nucleotides labeled with fluorescein family dyes is measured by ddNTP incorporation assays. One such assay is a primer extension competition assay conducted under conditions of limiting template. In this assay, a primer DG48 (5'-GGGAAGGGCGATCGGTGCGGGCCTCTCTCGC), (SEQ ID NO: 11), bound to M13mp18 template (Innis *et al.*, 1988, Proc. Natl. Acad. Sci. USA 85:9436) is extended in the presence of [α -³²P]dCTP and excess enzyme with various levels of a fluorescently labeled ddNTP, Zowie-ddCTP. Because the incorporation of a ddCTP residue terminates the extension reaction, the more readily a DNA polymerase incorporates a ddCTP into an extended primer, the less [α -³²P]dCTP can be incorporated. Thus, as the efficiency of fluorescently labeled ddCTP incorporation increases, the extent of inhibition of DNA synthesis is increased. The reactions were also performed with various levels of an unlabeled ddCTP. The concentrations of ddCTP and Zowie-ddCTP needed for 50% inhibition were calculated and compared to give a relative measure of the ability of the enzyme to incorporate the fluorescently-labeled nucleotide. The details of the ddNTP incorporation assay are provided in Example II.

[0051] Thus, in one embodiment of the invention, the characteristic of reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes is measured by the fluorescent ddNTP incorporation assay described in Example II. In a preferred embodiment, the concentration of a ddNTP labeled with a fluorescein dye, Zowie-ddCTP, required for 50% inhibition of DNA synthesis is reduced at least 3-fold for a mutant enzyme of the invention, relative to the wild-type enzyme. In a more preferred embodiment, the concentration is reduced at least 5-fold. In a most preferred embodiment, the concentration is reduced at least 10-fold. In another embodiment, the characteristic of reduced discrimination is assayed by measuring fluorescent dNTP incorporation.

[0052] In another aspect of the invention, the thermostable DNA polymerase gene sequence and enzyme are derived from various thermophilic species. In one embodiment, the polymerase gene sequence and enzyme are from a species of the genus *Thermus*. In other embodiments of the invention, the gene sequence and enzyme are from thermophilic species other than *Thermus*. The full nucleic acid and amino acid sequence for numerous thermostable DNA polymerases are available. The sequences each of *Taq*, *Thermus thermophilus* (*Tth*), *Thermus species* Z05, *Thermus species* sps17, *Thermotoga maritima* (*Tma*), and *Thermosipho africanus* (*Taf*) polymerase have been published in PCT International Patent Application No. PCT/U.S.91/07035 which published as PCT Patent Publication No. WO 92/06200 on April 16, 1992, and is incorporated herein by reference. The sequences for the DNA polymerase from *Thermus flavus*, *Bacillus caldotenax*, and *Bacillus stearothermophilus* have been published in Akhmetzjanov and Vakhitov, 1992, Nucleic Acids Research 20 (21):5839, Uemori *et al.*, 1993, J. Biochem. 113:401-410, and as accession number

BSU23149.ng from the NCBI New GenBank database, respectively, which are each incorporated herein by reference. The sequence of the thermostable DNA polymerase from *Thermus caldophilus* is found in EMBL/GenBank Accession No. U62584. The sequence of the thermostable DNA polymerase from *Thermus filiformis* can be recovered from ATCC Deposit No. 42380 using the methods provided in U.S. Patent No. 4,889,818, as well as the sequence information provided in Table 1. The sequence of the *Thermotoga neapolitana* DNA polymerase is from GeneSeq Patent Data Base Accession No. R98144 (also disclosed in PCT WO 97/09451).

Table I

<u>Organism</u>	<u>Critical Motif</u>	<u>Critical Amino Acid Position</u>
	↓	
Consensus	L S/a - - L/i - - - - E	
<i>Thermus aquaticus</i>	L S Q E L A I P Y E E	681
<i>Thermus flavus</i>	L S G E L S I P Y E E	679
<i>Thermus thermophilus</i>	L S Q E L A I P Y E E	683
<i>Thermus specie Z05</i>	L S Q E L A I P Y E E	683
<i>Thermus specie sps17</i>	L S Q E L S I P Y E E	679
<i>Thermus caldophilus</i>	L S Q E L A I P Y E E	683
<i>Thermus filiformis</i>	L S Q E L S I P Y E E	679
<i>Thermotoga maritima</i>	L S V R L G V P V K E	744
<i>Thermotoga neapolitana</i>	L S V R L G I P V K E	744
<i>Thermosipho africanus</i>	L S K R I G L S V S E	743
<i>Bacillus caldotenax</i> ¹	L A Q N L N I S R K E	725, 724
<i>Bacillus stearothermophilus</i> ²	L A Q N L N I T R K E	724, 727, 802

1. Protein sequence from Accession No. D12982, Uemori T., Ishino Y., Fujita K., Asada K., Kato I. "Cloning of the DNA polymerase gene of *Bacillus caldotenax* and characterization of the gene product" *J. Biochem.* 113:401 (1993). The critical residue in that sequence is 725. An almost identical protein sequence is provided as a putative "*Bacillus stearothermophilus*" DNA Polymerase in Accession No. R45155 and WPI 93 408323/51. The critical residue in that sequence is 724.

2. There are several sequence submissions for *Bacillus stearothermophilus* DNA polymerase in the GeneBank, or SwissProt/PIR databases. Although these sequences are highly related, but somewhat different from one another, each contains the identical L(S/A)XX(L/I)XXXXXE (SEQ ID NO: 9) motif, where X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuXaaXaaXaaXaaXaaXaaXaaXaaGlu (SEQ ID NO: 9), whereby "Xaa" at positions 3, 6, 7, 8, 9, and 10 are any amino acid, "Xaa" at position 2 is Ser or Ala, "Xaa" at position 4 is any amino acid except Glu, and "Xaa" at position 5 is Leu or Ile.

In the table above, protein sequences comprising the Critical Residue in the Critical Motif at position 724 are provided by Japanese patent publication J 05 304 964A, EP No. 699,760, and Accession No. U33536. Another highly related, but somewhat different, protein sequence was published in Gene 163:65-68(1995), contains the Critical Residue in the Critical Motif at position 727. Another highly related, but somewhat different, protein sequence, Accession No. U23149, for *Bst* DNA polymerase contains the Critical Residue in the Critical Motif at position 802.

[0053] Because the DNA polymerases of each thermophilic species are unique, the amino acid position of the region of criticality is distinct for each enzyme. Amino acid and nucleic acid sequence alignment programs are readily available and, given the particular region identified herein, serve to assist in the identification of the exact sequence region of the invention. Such sequence alignment programs are available from the Genetics Computer Group, 575 Science Drive, Madison, Wisconsin. Given the particular motif identified herein, these programs, including "GAP," "BESTFIT," and "PILEUP," serve to assist in the localization of the critical motif. The position of the regions of criticality are shown in Table I for thermostable DNA polymerases from exemplary thermophilic species.

[0054] Regardless of the exact position of the critical motif LSXXLX(V/I)PXXE (SEQ ID NO: 7), where X at position 4 is any amino acid except E, within the polymerase domain of a thermostable DNA polymerase, the presence of the motif serves to provide thermostable DNA polymerases having the ability to efficiently incorporate nucleotides labeled with fluorescein family dyes. Therefore, mutation of the conserved glutamic acid of the thermostable DNA polymerases of *Thermus flavus* (Glu 679), *Thermus thermophilus* (Glu 683), *Thermus species* Z05 (Glu 683), *Thermus species* sps17 (Glu 679) *Thermus caldophilus* (Glu 683), *Thermus filiformis* (Glu 679) to produce the critical motif will provide an enhancing effect on the ability of the polymerase to efficiently incorporate nucleotides labeled with fluorescein family dyes.

[0055] In addition, in view of the highly conserved nature of the now identified critical motif, novel thermostable DNA polymerases may be identified based upon their homology to, for example, *Taq* DNA polymerase or the sequences of other DNA polymerases in Table I (see for example U.S. Patent Nos. 5,618,711 and 5,624,833 which are herein incorporated by reference). Such polymerases, so long as their peptide sequence is at least 45% and most preferably greater than 80% homologous to the *Taq* polymerase amino acid sequence, as determined by the methods described herein, are within the scope of the present invention. Consequently, the invention relates to a class of enzymes which also includes, for example, the thermostable DNA polymerase, and corresponding gene and expression vectors from *Thermus oshimai* (Williams RA, et al., 1996 Int. J. Syst. Bacteriol 46 (2): 403-408); *Thermus silvanus* and *Thermus chliarophilus* (Tenreiro S, et al., 1995, Int. J. Syst. Bacteriol 45 (4): 633-639); *Thermus scotoductus* (Tenreiro S et al., 1995, Res. Microbiol 146 (4): 315-324); *Thermus ruber* ATCC 35948, (L.G. Loginova, 1984, Int. J. Syst. Bacteriol 34: 498-499); and *Thermus brockianus* (Munster, M.J., 1986, J. Gen. Microbiol 132: 1677), which publications are each incorporated herein by reference.

[0056] Those of skill in the art will recognize that the above thermostable DNA polymerases with enhanced efficiency for incorporating fluorescein-labeled nucleotides are most easily constructed by recombinant DNA techniques such as site-directed mutagenesis. See for example Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, 1989, second edition, chapter 15.51, "Oligonucleotide-mediated mutagenesis," which is incorporated herein by reference. This technique is now standard in the art, and can be used to create all possible classes of base pair changes at any determined site in a gene. The method is performed using a synthetic oligonucleotide primer complementary to a single-stranded phage or plasmid DNA to be mutagenized except for a limited mismatching, which represents the desired mutation. Briefly, the synthetic oligonucleotide is used as a primer to direct synthesis of a strand complementary to the phage or plasmid, and the resulting double-stranded DNA is transformed into a phage- or plas-

mid-supporting host bacterium. The resulting bacteria can be assayed by, for example, DNA sequence analysis or probe hybridization to identify those plaques or colonies carrying the desired mutated gene sequence.

[0057] Subsequent to the invention of PCR, primer-directed mutagenesis (described in U.S. Patent No. 4,683,195, which is herein incorporated by reference) and "overlap PCR" (Higuchi, 1989, in PCR Technology, ed. Erlich, Stockton Press, New York, NY, pp.61-70) have become routine means of introducing any mutation at any position of a gene.

[0058] The mutated DNA can be recovered from the plasmid, phasmid, phage or amplification reaction by conventional means and ligated into an expression vector for subsequent culture and purification of the resulting enzyme. Numerous cloning and expression vectors are suitable for practicing the invention, including mammalian and bacterial systems, as described in, for example, Sambrook *et al.*, 1989 *supra*. For convenience, the present invention is exemplified utilizing the lambda derived P_L promoter (Shimatake *et al.*, 1981, Nature 292:128). Use of this promoter is specifically described in U.S. Patent Nos. 4,711,845 and 5,079,352, which are incorporated herein by reference.

[0059] Plasmid pCS1 has been deposited with the ATCC, on August 28, 1997, and given accession No. 98521. This plasmid contains a gene encoding a thermostable DNA polymerase which gene is mutated at the codon at position 681 such that glutamic acid is replaced with lysine in the resulting polypeptide and provides a means for providing thermostable DNA polymerases having an enhanced efficiency for incorporating nucleotides labeled with fluorescein family dyes. Example I illustrates the use of flanking restriction sites suitable for subcloning the E681K mutation to create other thermostable DNA polymerase enzymes. Alternatively, because the complete gene sequence for numerous thermostable DNA polymerases are known, other means for introducing the E681K mutation, such as restriction digestion and fragment replacement, are readily available to those of skill in the art, having the availability of ATCC deposits and the sequence information provided herein.

[0060] When one desires to produce one of the mutant or native enzymes of the present invention, or a derivative or homologue of those enzymes, the production of the enzyme typically involves the transformation of a host cell with the expression vector, and culture of the transformed host cell under conditions such that expression will occur. Means for transforming and culturing transformed host cells are well known in the art and are described in detail in, for example, Sambrook *et al.*, 1989, *supra*.

[0061] The thermostable DNA polymerases of the present invention are generally purified from *E. coli* strain DG116 (deposited as ATCC 53606 on April 7, 1987) which has been transformed with an expression vector operably linked to a gene encoding a wild-type or modified thermostable DNA polymerase. Methods for purifying the thermostable DNA polymerase are described in, for example, Example I and Lawyer *et al.*, 1993, PCR Methods and Applications 2:275-87, which is incorporated herein by reference.

[0062] The thermostable enzymes of the invention may be used for any purpose in which such enzyme activity is necessary or desired. Examples of uses include DNA sequencing, DNA labeling, and labeling of primer extension products. DNA sequencing by the Sanger dideoxynucleotide method (Sanger *et al.*, 1977, Proc. Natl. Acad. Sci. 74: 5463) is particularly improved by the present invention. Advances in the basic Sanger *et al.* method have provided novel vectors (Yanisch-Pertion *et al.*, 1985 *Gene* 33:103-119) and base analogues (Mills *et al.*, 1979, Proc. Natl. Acad. Sci. 76:2232-2235, and Barr *et al.*, 1986, Biotechniques 4:428-432). In general, DNA sequencing requires template-dependent primer extension in the presence of chain-terminating base analogs, resulting in a distribution of partial fragments which are subsequently separated by size. The basic dideoxy sequencing procedure involves (i) annealing an oligonucleotide primer, optionally labeled, to a template; (ii) extending the primer with DNA polymerase in four separate reactions, each containing a mixture of unlabeled dNTPs and a limiting amount of one chain terminating agent such as a ddNTP, optionally labeled; and (iii) resolving the four sets of reaction products on a high-resolution denaturing polyacrylamide/urea gel. The reaction products can be detected in the gel by autoradiography or by fluorescence detection, depending on the label used, and the image can be examined to infer the nucleotide sequence. These methods utilize DNA polymerase such as the Klenow fragment of *E. coli* Pol I or a modified T7 DNA polymerase.

[0063] The availability of thermoresistant polymerases, such as *Taq* DNA polymerase, resulted in improved methods for sequencing with thermostable DNA polymerase (see Innis *et al.*, 1988, *supra*) and modifications thereof referred to as "cycle sequencing" (Murray, 1989, Nuc Acids Res. 17:8889). As an alternative to basic dideoxy sequencing, cycle sequencing is a linear, asymmetric amplification of target sequences complementary to the template sequence in the presence of chain terminators. A single cycle produces a family of extension products of all possible lengths. Following denaturation of the extension reaction product from the DNA template, multiple cycles of primer annealing and primer extension occur in the presence of terminators such as ddNTPs. Cycle sequencing requires less template DNA than conventional chain-termination sequencing. Thermostable DNA polymerases have several advantages in cycle sequencing; they tolerate the stringent annealing temperatures which are required for specific hybridization of primer to nucleic acid targets as well as tolerating the multiple cycles of high temperature denaturation which occur in each cycle, i.e., 90-95° C. For this reason, Ampli *Taq*[®] DNA Polymerase and its derivatives and descendants have been included in *Taq* cycle sequencing kits commercialized by companies such as Perkin-Elmer, Norwalk, CT.

[0064] Two variations of chain termination sequencing methods exist - dye-primer sequencing and dye-terminator sequencing. In dye-primer sequencing, the ddNTP terminators are unlabeled, and a labeled primer is utilized to detect

extension products (Smith *et al.*, 1986, *Nature* 32:674-679). In dye-terminator DNA sequencing, a DNA polymerase is used to incorporate dNTPs and fluorescently labeled ddNTPs onto the end of a DNA primer (Lee *et al.*, *supra.*). This process offers the advantage of not having to synthesize dye labeled primers. Furthermore, dye-terminator reactions are more convenient in that all four reactions can be performed in the same tube.

[0065] Both dye-primer and dye-terminator methods may be automated using an automated sequencing instrument produced by Applied Biosystems, Foster City, CA. (U.S. Patent No. 5,171,534, which is herein incorporated by reference). When using the instrument, the completed sequencing reaction mixture is fractionated on a denaturing polyacrylamide gel mounted in the instrument. A laser at the bottom of the instrument detects the fluorescent products as they are electrophoresed according to size through the gel.

[0066] Two types of fluorescent dyes are commonly used to label the terminators used for dye-terminator sequencing - negatively charged and zwitterionic fluorescent dyes. Negatively charged fluorescent dyes include those of the fluorescein and BODIPY families. BODIPY dyes (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) are described in International Patent Application, Publication No. WO 97/00967, which is incorporated herein by reference. Zwitterionic fluorescent dyes include those of the rhodamine family. Commercially available cycle sequencing kits use terminators labeled with rhodamine derivatives. However, the rhodamine-labeled terminators are rather costly and the product must be separated from unincorporated dye-ddNTPs before loading on the gel since they co-migrate with the sequencing products. Rhodamine dye family terminators seem to stabilize hairpin structures in GC-rich regions, which causes the products to migrate anomalously. This requires the use of dITP which relaxes the secondary structure but also affects the efficiency of incorporation of terminator.

[0067] In contrast, fluorescein-labeled terminators eliminate the separation step prior to gel loading since they have a greater net negative charge and migrate faster than the sequencing products. In addition, fluorescein-labeled sequencing products have better electrophoretic migration than sequencing products labelled with rhodamine. Although wild-type *Taq* DNA polymerase does not efficiently incorporate terminators labeled with fluorescein family dyes, this can now be accomplished efficiently by use of the modified enzymes provided herein.

[0068] Thus, the scope of this invention includes novel methods for dideoxy sequencing using enzymes having the critical motif, as well as kits for performing the method. In one embodiment, the sequencing method of the invention comprises:

a) providing a recombinant thermostable DNA polymerase enzyme which is characterized in that

i) in its native form said polymerase comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1), where X is any amino acid,

ii) the X at position 4 in said sequence is mutated in comparison to said native sequence, except that X is not mutated to E; and

iii) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison to the native form of said enzyme; and

b) performing a dye-terminator sequencing reaction.

[0069] In a preferred embodiment of the above method, the native form enzyme has the amino acid sequence LS(Q/G)XL(S/A)IPYEE (SEQ ID NO: 2), where X is any amino acid. In the three-letter code, this amino acid sequence is represented as LeuSerXaaXaaLeuXaalleProTyrGluGlu (SEQ ID NO: 2), whereby "Xaa" at position 3 is Gln or Gly, "Xaa" at position 4 is any amino acid, and "Xaa" at position 6 is Ser or Ala. In a more preferred embodiment, the native form amino acid sequence is LSQXLAIPYEE (SEQ ID NO:3), where X is any amino acid. In the three-letter code, this amino acid sequence is represented as LeuSerGlnXaaLeuAlalleProTyrGluGlu (SEQ ID NO:3), whereby "Xaa" at position 4 is any amino acid. In a most preferred embodiment, the "Xaa" at position 4 is Lys.

[0070] As described above, DNA sequencing with thermostable DNA polymerases requires a mixture of unconventional base analogues that act as chain-terminators and conventional nucleotides at a specified ratio of concentrations that insures that a population of extension products would be generated representing all possible fragment lengths over a distance of several hundred bases. Some thermostable DNA polymerases previously used for sequencing, such as wild-type *Taq* polymerase, are characterized in that they preferentially incorporate conventional nucleotides in the presence of a mixture of conventional and unconventional nucleotides. However, some recently described thermostable DNA polymerases allow the ratio of unconventional base analogues to conventional bases to be reduced from a hundred to several hundred fold, or up to over a thousand fold.

[0071] One such polymerase is the F667Y mutant of *Taq* DNA polymerase. Another such mutant is a *Taq* DNA polymerase having an F667Y mutation and a mutation at position 46 which changes a glycine residue to an aspartic acid residue (G46D) mutation. This mutant polymerase, known as *AmpliTaq*, FS, is manufactured by Hoffmann-La Roche and marketed by Perkin-Elmer. F730YTma30 DNA Polymerase is another such polymerase. This mutant

polymerase is a combination of 1) nucleotides 1-570 of *Taq* DNA polymerase modified to encode a G46D mutation and 2) nucleotides 571-2679 of *Tma* DNA polymerase modified to encode an aspartic acid to alanine mutation at position 323, a glutamic acid to alanine mutation at position 325, and a phenylalanine to tyrosine mutation at position 730 (U.S. Patent Application Serial No. 60/052065 and European Patent Application No. 98112327.6, both hereby incorporated by reference). Another polymerase that incorporates unconventional base analogues is a F730Y mutant DNA polymerase from *Thermotoga neapolitana* (International Patent Application, Publication Nos. WO 96/10640, WO 96/41014, and WO 97/09451, which are hereby incorporated by reference). Using these enzymes, for a given dNTP concentration, the rhodamine-ddNTP concentration can be decreased by about 50- to several hundred-fold compared to thermostable DNA polymerases previously available.

[0072] The E681K mutation of the invention was combined using recombinant DNA methods with an F667Y mutation to produce the double mutant *Taq* DNA polymerase enzyme used in the sequencing reactions described in Example IV. The double mutant was used in a dye-terminator sequencing reaction with fluorescein-labeled dye terminators. The results, described in Example IV, show that the enzyme is capable of incorporating fluorescein-labeled dye terminators in a sequencing reaction and produces sequencing ladders that can be accurately read in an automated sequencing instrument. Unexpectedly, the combination of the E681K and the F667Y mutations was also found to produce a thermostable DNA polymerase enzyme with a 3- to 4-fold increased extension rate relative to an enzyme with the F667Y mutation alone, as measured by the assay described in Example III.

[0073] Thus, in another aspect of this invention, the critical motif identified in this invention can be combined with motifs conferring reduced discrimination against ddNTPs to produce polymerases having an increased efficiency of incorporation of both labeled and unlabeled ddNTPs. These polymerases are useful in DNA sequencing methods. In one embodiment of the present invention, a thermostable DNA polymerase having the critical motif defined herein also comprises the critical motif that includes the F667Y mutation, described in U.S. Serial No 08/448,223. In this embodiment, the thermostable DNA polymerase is characterized in that

- i) in its native form said polymerase comprises a first amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1), where X is any amino acid,
- ii) the X at position 4 in said first amino acid sequence is mutated in comparison to said native sequence, except that X is not mutated to E; and
- iii) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison to the native form of said enzyme; and
- iv) said polymerase comprises a second amino acid sequence MRRXXKXXNXXXXYG (SEQ ID NO: 12) where X is any amino acid;
- v) said thermostable DNA polymerase also has reduced discrimination against incorporation of unconventional nucleotides in comparison to the native form of said enzyme. In the three-letter code, the second amino acid sequence is represented by MetArgArgXaaXaaLysXaaXaaAsnTyrXaaXaaXaaTyrGly (SEQ ID NO: 12), where "Xaa" at positions 4, 5, 7, 8, 11, 12, and 13 is any amino acid. In a preferred embodiment, the "Xaa" at position 4 in the first amino acid sequence is mutated to Lys. In a more preferred embodiment, the enzyme is *Taq* DNA polymerase and it comprises the E681K and F667Y mutations. Also within the scope of this invention are methods of sequencing using the above polymerases.

[0074] Also within the scope of this invention is the improved sequencing method of the invention performed using thermostable DNA polymerase enzymes having a critical motif which is not derived by mutation, but which critical motif exists as a natural variant. In this aspect, the DNA polymerase of a thermophilic bacterial species has a critical motif in which the residue at position 4 is not Glu. For example, in the thermostable DNA polymerase from *Thermotoga neapolitana*, the X at position 4 in the motif LSXXLX(V/I)PXXE (SEQ ID NO: 7), where X is any amino acid except E, is an arginine residue. Thus, the invention provides for improved methods of DNA sequencing using a native thermostable DNA polymerase which comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 7) where X can be any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerXaaXaaLeuXaaXaaProXaaXaaGlu (SEQ ID NO: 7), where "Xaa" at positions 3, 6, 9, and 10 are any amino acid and "Xaa" at position 4 is any amino acid except Glu and "Xaa" at position 7 is Val or Ile. In this embodiment, the sequencing method of the invention comprises:

- a) providing a thermostable DNA polymerase which is characterized in that

- i) said polymerase comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 7), where X at position 4 is any amino acid except E,
- ii) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes; and

- b) providing a dye-terminator labeled with a fluorescein family dye, and
- c) performing a dye-terminator sequencing reaction.

[0075] In a more preferred embodiment, the sequencing method of the invention comprises:

- a) providing a thermostable DNA polymerase which is characterized in that

- i) said polymerase comprises a first amino acid sequence

- LSXXLX(V/I)PXXE (SEQ ID NO: 7), where X at position 4 is any amino acid except E,

- ii) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes;

- iii) said polymerase comprises a second amino acid sequence MRRXXKXXNYXXXYG (SEQ ID NO: 12) where X is any amino acid.

- iv) said thermostable DNA polymerase has reduced discrimination against incorporation of unconventional nucleotides; and

- b) providing a dye-terminator labeled with a fluorescein family dye, and

- c) performing a dye-terminator sequencing reaction.

[0076] In another preferred embodiment, the enzyme comprises the amino acid sequence LS(Q/G)XL(S/A)IPYEE (SEQ ID NO: 13), where X at position 4 is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerXaaXaaLeuXaalleProTyrGluGlu (SEQ ID NO: 13) whereby "Xaa" at position 3 is Gln or Gly, "Xaa" at position 4 is any amino acid except Glu, and "Xaa" at position 6 is Ser or Ala. In a more preferred embodiment, the amino acid sequence is LSQXLAIPYEE (SEQ ID NO: 14), where X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerGlnXaaLeuAlalleProTyrGluGlu (SEQ ID NO: 14), whereby "Xaa" at position 4 is any amino acid except Glu.

[0077] In yet another preferred embodiment, the enzyme has the amino acid sequence LSVXLG(V/I)PVKE (SEQ ID NO: 15), where X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyXaaProValLysGlu (SEQ ID NO: 15), whereby "Xaa" at position 4 is any amino acid except Glu and "Xaa" at position 7 is Val or Ile. In a more preferred embodiment, the amino acid sequence is LSVXLGVPVKE (SEQ ID NO: 16), where X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyValProValLysGlu (SEQ ID NO: 16), whereby "Xaa" at position 4 is any amino acid except Glu. In a most preferred embodiment, the "Xaa" at position 4 is Arg. In another more preferred embodiment, the amino acid sequence is LSVXLGIPVKE (SEQ ID NO: 17), where X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlylleProValLysGlu (SEQ ID NO: 17), whereby "Xaa" at position 4 is any amino acid except Glu. In a most preferred embodiment, the "Xaa" at position 4 is Arg.

[0078] In another embodiment of the invention, the sequencing methods are performed using a native enzyme which has a reduced level of discrimination against nucleotides labeled with fluorescein family dyes which level is measured using a ddNTP incorporation assay such as that described in Example II. The concentration of ddCTP required for 50% inhibition of DNA synthesis is determined, as is the concentration of Zowie-ddCTP needed for 50% inhibition. The ratio of the concentration for Zowie-ddCTP to the concentration for ddCTP is calculated. In a preferred embodiment, the ratio is 10 or less. In a more preferred embodiment, the ratio is 4 or less. In a most preferred embodiment, the ratio is 1.2 or less.

[0079] Although the examples provided herein use dideoxynucleotides labeled with fluorescein family dyes, the use of other unconventional nucleotides and fluorescent dyes is also within the scope of this invention. Other unconventional nucleotides include fluorescently-labeled dNTPs, which can be used to label the products of DNA synthesis, and fluorescently-labeled rNTPs, which can be used to label the primer extension products. Other dyes include other negatively charged fluorescent dyes, such as BODIPY, which are structurally and chemically similar to fluorescein. Other dyes also include cyanine dyes. Cyanine-labeled dNTPs were added to a standard PCR reaction which included a *Taq* DNA polymerase with the E681K mutation (and a G46D mutation). The cyanine-labeled dNTPs were unexpectedly found to be incorporated into amplification products at a level that was higher than for the wild-type enzyme. Thus, in this aspect, a method of labeling DNA of the invention uses a native or mutant polymerase of the invention in combination with a nucleotide labeled with either a negatively charged fluorescent dye or a cyanine dye. In one embodiment, the DNA labeling method of the invention comprises:

- a) providing a thermostable DNA polymerase characterized in that

- i) said polymerase comprises the amino acid sequence

LSXXLX(V/I)PXXE (SEQ ID NO: 7) where X at position 4 can be any amino acid except E

ii) said polymerase has reduced discrimination against incorporation of unconventional nucleotides, and

b) providing a nucleotide labeled with a negatively charged fluorescent dye, and

c) performing a DNA synthesis reaction.

[0080] In another embodiment, the DNA labeling method of the invention comprises:

a) providing a thermostable DNA polymerase characterized in that

i) said polymerase comprises the amino acid sequence

LSXXLX(V/I)PXXE (SEQ ID NO: 7) where X at position 4 can be any amino acid except E

ii) said polymerase has reduced discrimination against incorporation of unconventional nucleotides, and

b) providing a nucleotide labeled with a cyanine dye, and

c) performing a DNA synthesis reaction.

[0081] In another aspect of the invention, a thermostable DNA polymerase is provided which combines a mutation allowing more efficient incorporation of rNTPs, such as the glutamic acid to glycine mutation at position 615 of *Taq* DNA polymerase, and the critical motif of this invention. The resulting enzyme is expected to have an increased efficiency of incorporation of ribonucleotides labeled with fluorescein family dyes. Thus, in one embodiment, the invention provides a recombinant thermostable DNA polymerase which (1) in its native form comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid and (2) the X at position 4 is mutated such that X at position 4 is not mutated to E and (3) also comprises the region of criticality which is amino acid sequence SQIXLR(V/I) (SEQ ID NO: 18) where "X" is any amino acid except E, and (4) is capable of efficient incorporation of ribonucleotides labeled with fluorescein family dyes. In the three-letter code, the latter sequence is represented as SerGlnIleXaa-LeuArgXaa, where "Xaa" at position 4 is any amino acid except Glu and "Xaa" at position 7 is Val or Ile

[0082] Mutant polymerase domains such as that for *Taq* containing the E615G and E681K mutations are useful in improved methods of producing primer extension products labeled with fluorescein family dyes. For example, in a primer extension reaction such as PCR, rNTPs labeled with fluorescein family dyes are substituted at least partially for one of the 4 standard dNTPs and a double mutant polymerase such as E681K E615G *Taq* DNA polymerase is included. The mutant polymerase synthesizes primer extension products that have fluorescein-labeled ribonucleotide residues at various positions along their lengths. Upon heat or alkali treatment, the primer extension products are fragmented at each ribonucleotide residue, producing a population of end-labeled fragments. This population of uniformly labeled fragments represents a distribution of the fluorescent label across the length of the primer extension product. Labeled fragments of these characteristics are useful in nucleic acid detection formats based on silicon chips, such as that of (Cronin *et al.*, *supra.*). Thus, in one embodiment, the invention provides a method of labeling primer extension products which comprises (1) providing a thermostable DNA polymerase which (a) in its native form comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid, (b) the X at position 4 is mutated such that X at position 4 is not mutated to E, (c) also comprises the region of criticality which is amino acid sequence SQIXLR(V/I) (SEQ ID NO: 18) where "X" is any amino acid except E and (d) is capable of efficient incorporation of ribonucleotides labeled with fluorescein and/or cyanine family dyes, and (2) performing a primer extension reaction.

[0083] In yet another aspect, enzymes having the critical motif of this invention display an increased rate of extension relative to the wild-type enzyme as shown in Example IV for a E681K F667Y mutant. In one embodiment, the enzyme is characterized in that (1) in its native form, it comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid, (2) the amino acid sequence is mutated at position 4 such that X at position 4 is not mutated to E, and (3) it has an increased extension rate relative to the wild-type enzyme. In a preferred embodiment, the enzyme is characterized in that (1) in its native form, it comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid, (2) the amino acid sequence is mutated at position 4 such that X at position 4 is not mutated to E and (3) it also comprises the amino acid sequence MRRXXKXXNXXXYG (SEQ ID NO: 12) where X is any amino acid and (4) has an increased extension rate. In a more preferred embodiment, the enzyme is characterized in that (1) in its native form it contains the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid and (2) the amino acid sequence is mutated at position 4 such that X at position 4 is mutated to K. In a most preferred embodiment, the enzyme is *Taq* DNA polymerase and contains the E681K mutation and the F667Y mutation. Also included within this aspect are methods of sequencing and labeling of DNA using the polymerases with increased extension rate as well as kits for doing the same.

[0084] In a preferred method for DNA sequencing according to the invention, thermostable pyrophosphatase is included in the reaction mixture. Pyrophosphatase has been shown to enhance sequencing data using mesophilic as

well as the mutant thermostable DNA polymerases described in European Patent Application, Publication No. EP-A-763 599 and U.S. Patent No. 5,665,551.

[0085] In an exemplified embodiment, the thermostable DNA polymerase of the invention also contains a mutation in the 5'-nuclease domain that serves to greatly attenuate this nuclease activity. Modified forms of *Taq* polymerase have been described in PCT Patent Publication No. WO 92/06200, published April 16, 1992 and in U.S. Patent No. 5,466,591. In one embodiment of that invention, the codon for the glycine residue at amino acid position 46 has been replaced with a codon for aspartic acid (G46D mutation). The resulting enzyme has enhanced utility in cycle sequencing reactions due to the decreased 5'-nuclease activity. The polymerase domain amino acid sequence and polymerase activity are both unchanged in the G46D mutant in comparison to the wild-type enzyme.

[0086] In a commercial embodiment of the invention, kits for practicing methods that are improved by use of the present invention are considered to be an additional aspect of the invention. One such kit for DNA sequencing comprises

a) a thermostable DNA polymerase characterized in that

i) said polymerase comprises the amino acid sequence

LSXXLX(V/I)PXXE (SEQ ID NO: 7) where X at position 4 can be any amino acid except E

ii) said polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes, and

b) a dye-terminator labeled with a negatively charged fluorescent dye and may additionally include other reagents for DNA sequencing such as dNTPs, thermostable pyrophosphatase and appropriate buffers. In another embodiment, the enzyme in the kit has the amino acid sequence LSVXLG(V/I)PVKE (SEQ ID NO: 15), whereby X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyXaaProValLysGlu (SEQ ID NO: 15), whereby "Xaa" at position 4 is any amino acid except Glu and "Xaa" at position 7 is Val or Ile. In a preferred embodiment, the amino acid sequence is LSVXLGVPVKE (SEQ ID NO: 16), where X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyValProValLysGlu (SEQ ID NO: 16), whereby "Xaa" at position 4 is any amino acid except E. In a more preferred embodiment, the "Xaa" at position 4 is Arg. In another preferred embodiment, the amino acid sequence is LSVXLGIPVKE (SEQ ID NO: 17) where X is any amino acid except E. In the three-letter code, this amino acid sequence is represented as LeuSerValXaaLeuGlyIleProValLysGlu (SEQ ID NO: 17), whereby "Xaa" at position 4 is any amino acid except Glu. In a more preferred embodiment, the "Xaa" at position 4 is Arg.

[0087] Other kits for DNA sequencing comprise a mutant thermostable DNA polymerase characterized in that

a) in its native form said polymerase comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid,

b) said amino acid sequence is mutated at position 4, except that X at position 4 is not mutated to E; and

c) said thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes in comparison to the native form of said enzyme and may additionally include reagents for DNA sequencing such as chain terminating compounds, dNTPs, thermostable pyrophosphatase and appropriate buffers. Where the terminators are labeled, preferable labels are fluorescent dyes, more preferable labels are negatively charged fluorescent dyes or cyanine dyes, and the most preferable labels are fluorescein family dyes. In a preferred embodiment, the enzyme in the kit has the amino acid sequence LS(Q/G)XL(S/A)IPYEE (SEQ ID NO: 2), where X is any amino acid. In the three-letter code, this amino acid sequence is represented as LeuSerXaaXaaLeuXaalleProTyrGluGlu (SEQ ID NO: 2), whereby "Xaa" at position 3 is Gln or Gly, "Xaa" at position 4 is any amino acid, and "Xaa" at position 6 is Ser or Ala. In a more preferred embodiment, the amino acid sequence is LSQXLAIPYEE (SEQ ID NO: 3), where X is any amino acid. In the three-letter code, this amino acid sequence is represented as LeuSerGlnXaaLeuAlalleProTyrGluGlu (SEQ ID NO: 3), whereby "Xaa" at position 4 is any amino acid. In a most preferred embodiment, the "Xaa" at position 4 is Lys.

[0088] Kits for labeling DNA comprise a thermostable DNA polymerase which is characterized in that (a) in its native form, the polymerase comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid, (b) the X at position 4 in said sequence is mutated in comparison to said native form, except that X at position 4 is not mutated to E, and c) the enzyme has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes, in comparison to the corresponding wild-type enzyme and may additionally include dNTPs and appropriate buffers. In a preferred embodiment, the X at position 4 is mutated to K. Other kits for producing labeled DNA comprise a) a nucleotide or nucleotide analog labeled with a negatively charged fluorescent compound and b) a native

thermostable DNA polymerases having the following critical motif:

LSXXLX(V/I)PXXE (SEQ ID NO: 7)

where X at position 4 can be any amino acid except E and said polymerase has reduced discrimination against incorporation of fluorescein-labeled nucleotides, and may additionally include dNTPs and appropriate buffers. In a preferred embodiment, the X at position 4 is K. In another preferred embodiment, the X at position 4 is R.

[0089] Kits for labeling primer extension products comprise a thermostable DNA polymerase which is characterized in that (a) in its native form, the polymerase comprises the amino acid sequence LSXXLX(V/I)PXXE (SEQ ID NO: 1) where X is any amino acid, (b) the X at position 4 in said sequence is mutated in comparison to said native sequence, except that X at position 4 is not mutated to E, c) the polymerase also comprises the second amino acid sequence SQIXLR(V/I) (SEQ ID NO: 18) where "X" is any amino acid except E, d) the enzyme has reduced discrimination against incorporation of ribonucleotides labeled with fluorescein family dyes, in comparison to the corresponding wild-type enzyme, and may additionally include a ribonucleotide or ribonucleotide analog labeled with a negatively charged fluorescent compound or cyanine compound, dNTPs, and appropriate buffers. In a preferred embodiment, the polymerase contains a E681K mutation and a E615G mutation. Other kits for producing labeled primer extension products comprise a) a ribonucleotide or ribonucleotide analog labeled with a negatively charged fluorescent compound or cyanine compound and b) a native thermostable DNA polymerase characterized in that it (i) comprises the critical motif which is the amino acid sequence:

LSXXLX(V/I)PXXE (SEQ ID NO: 7)

where X at position 4 can be any amino acid except E, (ii) comprises the second amino acid sequence SQIXLR(V/I) where "X" is any amino acid except E, and (iii) has reduced discrimination against incorporation of fluorescein-labeled ribonucleotides, and may additionally include dNTPs and appropriate buffers. In a preferred embodiment, in the first amino acid sequence, the X at position 4 is a K and in the second amino acid sequence, the X is a G. In another preferred embodiment, in the first amino acid sequence, the X at position 4 is a R and in the second amino acid sequence, the X is a G.

[0090] The following examples are offered by way of illustration only and are by no means intended to limit the scope of the claimed invention.

Example I

Expression of a Modified *Taq* Polymerase Gene Having Reduced Discrimination Against Nucleotides Labeled with Fluorescein Family Dyes

[0091] The C-terminal amino acid portion of *Taq* DNA polymerase encodes the polymerase active site domain (Lawyer *et al.*, 1993, *PCR Methods and Applications* 2:275-287, Freemont *et al.*, 1986, *Proteins: Structure, Function and Genetics* 1:66-73, which are incorporated herein by reference). A DNA fragment containing this region was isolated from the full-length *Taq* gene and mutagenized by PCR amplification in the presence of manganese (Leung *et al.*, 1989, *Technique* 1(1): 11-15). For this example, all restriction enzymes were purchased from New England Biolabs, Beverly MA. The mutagenized fragments were digested with *Pst*I and *Bgl*II and cloned into a *Taq* expression plasmid, pLK102, which had been digested with *Pst*I and *Bgl*II. Plasmid pLK102 is a derivative of pLK101 in which the 900 bp *Pst*I-*Bgl*II fragment is replaced by a short *Pst*I-*Bgl*II linker. Plasmid pLK101 is a modified form of pSYC1578 (Lawyer *et al.*, 1993, *supra* and U.S. Patent No. 5,079,352), in which the small *Hinc*II/*Eco*RV fragment located 3' to the polymerase coding region was deleted.

[0092] The resulting expression plasmids were transformed into *E. coli* strain N1624 (available from the *E. coli* Genetic Stock Center at Yale University, strain No. CGSC #5066) and the resulting transformants were screened for the ability to more efficiently incorporate [α -³²P]Tet-dCTP in comparison to the wild-type enzyme. Using this procedure Mutant CS1, was identified as having the ability to more efficiently incorporate [α -³²P]Tet-dCTP. The mutagenized *Taq* expression plasmid of mutant CS1 was digested with *Hind*III/*Nhe*I and the resulting restriction fragment was subcloned into the wild-type gene of pLK101, replacing the unmutagenized *Hind*III/*Nhe*I fragment, to determine which portion of the mutagenized *Taq* polymerase gene was responsible for the altered phenotype. Subclones containing the *Hind*III/*Nhe*I restriction fragment conferred the altered phenotype on the wild-type enzyme, indicating that the mutation was within this fragment. Subsequent subclone analysis determined that the mutation was located in the 265 bp *Bam*HI-*Nhe*I fragment.

[0093] DNA sequence analysis of the 265 *Nhe*I-*Bam*HI fragment was performed on pCS1 using the *Taq*FS DyeDeoxy™ Terminator Cycle Sequencing Kit from Applied Biosystems, Foster City, CA, and the Applied Biosystems Model Prism 377 DNA Sequencing System. The sequence analysis identified a missense mutation in the *Taq* polymerase gene at amino acid position 681, that caused a Glutamic acid (E) residue to be replaced by a Lysine (K) residue. Numbering is initiated at the codon encoding the first methionine residue of the mature protein, as in U.S. Patent No. 5,079,352, which is herein incorporated by reference. This mutation, E681K, specifically was caused by a GAG to AAG

change in the codon sequence. Plasmid pCS1 was deposited with the ATCC on August 28, 1997, and given accession No. 98521.

[0094] Plasmid pCS1 may contain additional mutations in the coding sequence for *Taq* polymerase; however, by further subcloning experiments, the E681K mutation was determined to be solely responsible for the increased efficiency in incorporation of nucleoside triphosphates labeled with fluorescein dyes. This point mutation is located in the 265 base pair *Bam*HI-*Nhe*I DNA fragment shown in Figure 1. Within the 265 bp DNA fragment, the E681K mutation is the only change from the wild-type *Taq* polymerase gene sequence.

[0095] For further analysis and quantitation of the efficiency of incorporation of nucleotide analogues, the 265 bp *Bam*HI-*Nhe*I fragment of plasmid pCS1 was cloned into a *Taq* expression vector that contained the wild-type sequence within the polymerase domain, pRDA3-2. Plasmid pRDA3-2 referred to as clone 3-2, is fully described in PCT Patent Publication No. WO 92/06200, which is incorporated herein by reference. A second clone encoding both the E681K mutation as well as a F667Y mutation was created by primer-directed mutagenesis and subsequent cloning of a PCR product containing both mutations into the *Bam*HI-*Nhe*I sites of plasmid pRDA3-2.

[0096] Expression vector pRDA3-2 contains the full-length *Taq* DNA polymerase gene operably linked to the phage lambda P_L promoter. In vector pRDA3-2, the 5'-nuclease domain of the *Taq* DNA polymerase gene contains a point mutation at the codon encoding glycine at position 46 that reduces 5'-nuclease activity (G46D mutation). However, the gene sequence within the polymerase domain of the expression vector pRDA3-2 is identical to the wild-type *Taq* DNA polymerase gene sequence. Plasmids, pRDA3-2, pCS1 and the E681K F667Y PCR product were digested with *Bam*HI and *Nhe*I and the 265 bp DNA fragment from plasmid pCS1 or the PCR product was ligated into vector pRDA3-2 by conventional means. The resulting plasmids, pLK112 and pLK113, respectively, were transformed into *E. coli* strain DG116 (ATCC No. 53606). These plasmids encode thermostable DNA polymerases herein referred to as G46D E681K *Taq* and G46D E681K F667Y *Taq*, respectively. The expressed thermostable DNA polymerase protein G46D E681K F667Y-*Taq* was purified according to the method described by Lawyer *et al.*, 1993, *supra*.

[0097] The G46D E681K *Taq* enzyme was purified using a similar, but smaller scale preparation method as follows: All steps were performed at 4° C unless indicated otherwise. Cells from a 475 ml culture were resuspended in 30 ml of buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA, pH 8.0, 0.5 mM Pefabloc®SC, 0.5 µg/ml leupeptin, 0.1 mM Nα-p-tosyl-L-Lysine Chloromethyl Ketone, 1 mM DTT). Cells were sonicated at 50% duty cycle, setting 5 for 1 minute, and cooled on ice for 1 minute. This step was repeated twice more. Then 1.5 ml of 4.0 M ammonium sulfate was added and the mixture heated in a 75°C water bath for 15 minutes, followed by cooling on ice. Polyethyleneimine was added to 0.6% and the mixture was incubated on ice for 10 minutes. The mixture was centrifuged at 16,000xg for 30 minutes. The supernatant was loaded on a 1.8 ml volume phenyl-sepharose column (Bio-rad Polyprep chromatography column) equilibrated with a solution of 50 mM Tris-HCl, pH 7.5, 10 mM EDTA, pH 8.0, 1 mM DTT, 0.2 M (NH₄)₂SO₄. The column was washed with 6 ml each of three solutions: 1) 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 0.2 M (NH₄)₂SO₄, 2) 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, and 3) 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 20 % ethylene glycol. The polymerase was eluted with 6 ml of 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 20% ethylene glycol, 2.5 M urea. After adjusting the polymerase preparation to 100 mM KCl with 3M KCl, the mixture was loaded on a heparin-sepharose column (1.8 ml volume, Bio-rad Poly-prep column) equilibrated in 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 100 mM KCl. After a wash with the same buffer, the sample was eluted in a buffer of 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 400 mM KCl.

[0098] Following purification, the activity of the modified enzymes was determined by the activity assay described in Lawyer *et al.*, 1989, *J. Biol. Chem.* 264:6427-6437, which is incorporated herein by reference. The activity of the purified enzymes was calculated as follows: one unit of enzyme corresponds to 10 nmoles of product synthesized in 30 min. DNA polymerase activity is linearly proportional to enzyme concentration up to 80-100 pmoles dCMP incorporated (diluted enzyme at 0.024-0.03 units/µl). The purified enzymes were utilized in the incorporation and sequencing reactions described in Examples II-IV.

Example II

Assay to Compare Efficiency of Incorporation of ddNTPs

[0099] The relative abilities of G46D F667Y *Taq*, G46D F667Y E681K *Taq* and F730Y *Tma*30 DNA polymerases to incorporate a fluorescein dye family-labeled ddCTP were compared by use of a limiting template, primer extension competition assay. F730Y *Tma*30 DNA polymerase is described in Example I of U.S. Serial No 60/052065, filed July 9, 1997 and in European Patent Application No. 98112327.6, both herein incorporated by reference. In this competition assay, because the incorporation of a ddCTP terminates the extension reaction, the more readily the polymerase incorporates a ddCTP into an extended primer, the less [α -³²P]dCTP can be incorporated. Thus, as the efficiency of ddCTP incorporation increases, the extent of inhibition of DNA synthesis is increased. The efficiency of incorporation of ddCTP is then compared to the efficiency of incorporation of fluorescently labeled ddCTP to give a relative measurement of the

efficiency of incorporation of fluorescently-labeled ddNTPs for a given enzyme.

[0100] The assay was performed as previously described (Lawyer *et al.*, 1989, *J. Biol. Chem.* 264:6427) including the following modifications. The assay mixture was composed so the final concentration was 50 mM Bicine pH 8.3, 25° C, 2.5 mM MgCl₂, 1 mM β-mercaptoethanol, 20 μM each of dATP, dGTP and dTTP (Perkin-Elmer), 20 μM dCTP (Perkin-Elmer) and [α-³³P]dCTP (New England Nuclear, Boston, MA). M13mp18 (Perkin-Elmer) was annealed to primer DG48, (SEQ ID NO: 10) and the equivalent of 0.085 pmoles of the annealed template was added to the assay mixture for each reaction. Thirty-five μl of the assay mixture with template DNA was added to each of 380.5 ml eppendorf tubes. Dilutions of Zowie-ddCTP in 25 mM CAPSO buffer, pH 9.6 were prepared such that when 10 μl of each was added to the reaction tube, the final concentration of Zowie-ddCTP would be 3, 1, 0.5, 0.25, 0.125, or 0.0625 μM. For G46D F667Y Taq DNA polymerase, two tubes each of the 3, 1, 0.5, 0.25, 0.125 μM Zowie-ddCTP were prepared. For G46D F667Y E681K Taq and F730Y Tma30 DNA polymerases, two tubes each of the 1, 0.5, 0.25, 0.125, and 0.0625 μM Zowie-ddCTP were prepared. The eight remaining reaction tubes received 10 μl of 25 mM CAPSO buffer, pH 9.6. Thus, each of the thirty-eight tubes contained 35 μl of assay mix and 10 μl of either 25 mM CAPSO buffer, pH 9.6 or one of the Zowie-ddCTP dilutions.

[0101] For each enzyme to be tested, polymerization was initiated in one tube of each Zowie-ddCTP dilution and two tubes containing the CAPSO buffer alone using 5 μl of the enzyme. The following concentrations of the enzymes were used, each predetermined to be an excess amount of enzyme for the amount of substrate in the assay: 2.5 units of F667Y G46D Taq DNA polymerase prepared as in Example I; 1.25 units of G46D, F667Y, E681K Taq DNA polymerase, prepared as in Example I; or 2 units of F730Y Tma30 DNA polymerase. As a control for the level of background, the remaining negative control was initiated with enzyme dilution buffer rather than polymerase. All reaction tubes were immediately vortexed briefly and incubated for 10 minutes at 75° C. The reactions were stopped by addition of 10 μl 60 mM EDTA and stored at 0° C.

[0102] In an analogous experiment, ddCTP was diluted in 25 mM CAPSO buffer, pH 9.6 such that when 10 μl of each dilution was added to the reaction tubes, the final concentration would be 0.5, 0.25, 0.125, 0.0625, or 0.0312 μM. Ten μl of each dilution was pipetted into each of three 0.5 ml Eppendorf tubes containing 35 μl of the assay mixture as described above. Four tubes containing 35 μl of the assay mix plus 10 μl of 25 mM CAPSO buffer, pH 9.6 were also prepared. Thus, each of the 19 tubes contained 35 μl of assay mix and 10 μl each of either 25 mM CAPSO, pH 9.6 or one of the ddCTP dilutions.

[0103] Polymerization was initiated in one tube of each ddCTP dilution and one tube of CAPSO buffer with 2.5 units of G46D F667Y Taq DNA polymerase, 1.25 units of G46D F667Y E681K Taq DNA polymerase or 2 units of F730Y Tma30 DNA polymerase. The remaining tube containing CAPSO was initiated with enzyme dilution buffer rather than the polymerase-containing buffer as a negative control. All reactions were immediately vortexed and incubated 10 minutes at 75° C. The reactions were stopped by addition of 10 microliters of 60 mM EDTA and stored at 0° C.

[0104] For each reaction, a 50 μl aliquot of the 60 μl reaction was diluted with 1 ml 2 mM EDTA, 50 μg/ml sheared salmon sperm DNA as a carrier. The DNA was precipitated with TCA using standard procedures and collected on GF/C filter discs (Whatman). The amount of incorporated [α-³³P]dCMP was determined for each sample and normalized to the CAPSO samples without ddNTP (0% inhibition). The concentration of ddCTP or Zowie-ddCTP needed for 50% inhibition was calculated for each sample and is shown in Table 2. Comparison of the amount of ddCTP needed to inhibit synthesis 50% with the amount of Zowie-ddCTP required to inhibit synthesis by 50% for a particular enzyme reflects the relative ability of each enzyme to incorporate fluorescently-labeled analog. These data show that G46D F667Y Taq DNA polymerase incorporates Zowie-ddCTP least efficiently of the three enzymes tested (ratio of concentrations for 50% inhibition by Zowie-ddCTP vs. ddCTP = 25). F730Y Tma30 DNA polymerase incorporates this labeled analog more efficiently than G46D F667Y Taq DNA polymerase (ratio of concentrations for 50% inhibition by Zowie-ddCTP vs. ddCTP = 4), while G46D F667Y E681K Taq DNA polymerase incorporates labeled and unlabeled ddCTP with nearly equal efficiency (ratio of concentrations for 50% inhibition by Zowie-ddCTP vs. ddCTP=1.2).

Table 2

Concentration (μM) of Zowie-ddCTP or ddCTP needed for 50% inhibition			
DNA polymerase	Zowie-ddCTP	ddCTP	Zowie-ddCTP/ddCTP
G46D F667Y Taq	1.4	0.056	25
G46D F667Y E681K Taq	0.14	0.116	1.2
F730Y Tma30	0.236	0.057	4

Example IIIExtension Rate Assay

[0105] The extension rate of G46D F667Y *Taq* and G46D F667Y E681K *Taq* were determined using an extension rate assay. In this experiment, the enzymes were used to extend a primer annealed to an M13 template in the presence of [α - 33 P]dCTP. The extension reactions were denatured and the products analyzed by denaturing agarose gel electrophoresis.

[0106] The assay was performed as previously described (Lawyer *et al.*, 1989, *J. Biol. Chem.* 264:6427) including the following modifications. The assay mixture was composed so the final concentration was 50 mM Bicine pH 8.3, 25° C, 2.5 mM MgCl₂, 1 mM β -mercaptoethanol, 200 μ M each of dATP, dGTP and dTTP (Perkin-Elmer), 100 μ M dCTP (Perkin-Elmer) containing [α - 33 P]dCTP (New England Nuclear, Boston, MA). M13mp18 (Perkin-Elmer) was annealed to primer DG48, (SEQ ID NO: 11), and the equivalent of 0.085 pmoles of the annealed template was added to the assay mixture for each reaction. Forty-five μ l of the assay mixture with template DNA was added to each of fourteen 0.5 ml eppendorf tubes. Each tube was preincubated at 75° C for at least 30 seconds before the start of the polymerase reaction.

[0107] Polymerization was initiated in six of the fourteen assay tubes with 5 μ l of G46D F667Y *Taq* DNA polymerase (2.5 units) or G46D F667Y E681K *Taq* DNA polymerase (1.25 units). Both enzymes were prepared as in Example I and the concentration used represents a predetermined excess amount of enzyme for the amount of substrate in the assay. As a control for the level of background, the remaining negative control was initiated with enzyme dilution buffer rather than polymerase. All reaction tubes were immediately vortexed briefly and incubated at 75° C. Two of the six tubes containing G46D F667Y *Taq* DNA polymerase were incubated 3 minutes, two for 6 minutes and two for 10 minutes. Similarly, two of the tubes started with G46D F667Y E681K *Taq* DNA polymerase were incubated for 30 seconds, two for 1 minute and two for 2 minutes. The control tubes were incubated for 3 minutes. The reactions were stopped by addition of 10 μ l 60 mM EDTA and stored at 0° C.

[0108] For each reaction, a 25 μ l aliquot of the 60 μ l reaction was diluted with 1 ml 2 mM EDTA, 50 μ g/ml sheared salmon sperm DNA as a carrier. The DNA was precipitated with TCA using standard procedures and collected on GF/C filter discs (Whatman). The amount of incorporated [α - 33 P]dCMP was determined for each sample.

[0109] The remaining 35 μ l of each duplicated were combined and the 70 μ l sample was ethanol precipitated, dried and resuspended in 50 mM NaOH, 1 mM EDTA. Aliquots were removed from these samples such that an equal number of [α - 33 P] counts were taken from each. These aliquots were loaded on an 0.9% alkaline agarose gel, electrophoresed, dried and autoradiographed as previously described (Maniatis *et al.*, 1982, In *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Bacteriophage lambda DNA cut with restriction enzyme *Hind*III (BRL) and 5' end-labeled with [32 P] was used as a molecular weight standard.

[0110] The length in base pairs of the extension product in each sample was determined by comparison of the migration distance of each sample with the distance migrated by the lambda DNA size standard. The number of base pairs in each product was divided by the number of seconds each extension reaction incubated to give the extension rate as shown below.

DNA polymerase	Time	Base Pairs/Sec
G46D F667Y <i>Taq</i>	3 min.	12.5
G46D F667Y <i>Taq</i>	6 min.	12.2
G46D F667Y <i>Taq</i>	10 min.	11.8
G46D F667Y E681K <i>Taq</i>	30 sec.	36.7
G46D F667Y E681K <i>Taq</i>	1 min.	41.7
G46D F667Y E681K <i>Taq</i>	2 min	52.9

[0111] These results indicate that the presence of the E681K mutation increases the extension rate of a G46D F667Y enzyme by 3- to 4.3- fold.

Example IVCycle Sequencing with G46D F667Y E681K *Taq* DNA Polymerase and Fluorescein Labeled ddNTPs

5 [0112] This example demonstrates the application of the modified polymerase of the invention to fluorescein dye labeled dideoxy terminator cycle sequencing, utilizing 1 μ M or less ddNTP and a ratio of ddNTP:dNTP of at least 1:100. The fluorescein dye labeled dideoxy terminators are reagents from the Applied Biosystems PRISM Sequenase[®] Terminator Sequencing Kits (Perkin-Elmer, Norwalk, CT) and were optimized for use with Sequenase DNA polymerase and alpha-thio dNTPs. Cycle sequencing reactions were performed in a 20 μ l volume containing 50 mM Tris-HCl (pH 8.8), 2.0 mM MgCl₂, 100 μ M each dATP, dCTP, and dTTP (Perkin-Elmer, Norwalk, CT), 500 μ M dITP (Pharmacia Bio-
10 tech, Piscataway, NJ), 0.2 μ g M13mp18 single-strand DNA template (Perkin-Elmer), 0.15 μ M LacZ Forward Primer (Perkin-Elmer), 5 units of G46D F667Y E681K *Taq* DNA polymerase, 20 units of *rTth* Thermostable Pyrophosphatase (European Patent Application, Publication No. EP-A-763 599 and U.S. Patent No. 5,665,551), 0.05 μ M Sequenase A Dye Terminator, 0.80 μ M Sequenase C Dye Terminator, 0.08 μ M Sequenase G Dye Terminator, and 1.0 μ M Sequenase
15 T Dye Terminator. All four Sequenase Dye Terminators were purchased from Perkin-Elmer. Reactions were placed in a preheated (75° C) Perkin-Elmer GeneAmp[®] PCR System 9600 thermal cycler and subjected to 25 cycles of 96° C for 10 seconds, 50° C for 5 seconds, and 60° C for 4 minutes. Dye labeled fragments were purified with Centri-Sep[™] columns (Princeton Separations, Adelphia, NJ) following the manufacturer's instructions and dried in a vacuum centrifuge. Pellets were resuspended in 6 μ l of deionized formamide:50 mg/mL Blue dextran (in 25 mM EDTA, pH 8.0) 5:1 (v/v),
20 heated at 90° C for 3 minutes, and directly loaded onto a pre-electrophoresed 4% polyacrylamide/6 M urea gel and electrophoresed and analyzed on a Perkin-Elmer ABI PRISM[®] 377 DNA Sequencer according to the manufacturer instructions (ABI PRISM 377 DNA Sequencer User's Manual). Automated base-calling by the Perkin-Elmer ABI PRISM 377 DNA Sequencer analysis software resulted in greater than 98.5% accuracy for 450 bases (6 errors for bases +10 to +460 from primer).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: F.Hoffmann-La Roche Ltd
(B) STREET: Grenzacherstrasse 124
(C) CITY: Basel
(D) STATE: BS
(E) COUNTRY: Switzerland
(F) POSTAL CODE (ZIP): CH-4070
(G) TELEPHONE: (0)61 688 24 03
(H) TELEFAX: (0)61 688 13 95
(I) TELEX: 962292/965312 hlr ch

(ii) TITLE OF INVENTION: Altered Thermostable DNA Polymerases
for Sequencing

(iii) NUMBER OF SEQUENCES: 18

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/052,065
(B) FILING DATE: 09-JUL-1997

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
(B) LOCATION: 7
(D) OTHER INFORMATION: /label= Xaa
/note= "Xaa at position 7 is Val or Ile."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Leu Ser Xaa Xaa Leu Xaa Xaa Pro Xaa Xaa Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region

(B) LOCATION: 3..6

(D) OTHER INFORMATION: /label= Xaa

/note= "Xaa at position 3 is Gln or Gly. Xaa at position 6 is Ser or Ala."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu Ser Xaa Xaa Leu Xaa Ile Pro Tyr Glu Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Leu Ser Gln Xaa Leu Ala Ile Pro Tyr Glu Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region

(B) LOCATION: 7

(D) OTHER INFORMATION: /label= Xaa

/note= "Xaa at position 7 is Val or Ile."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Leu Ser Val Xaa Leu Gly Xaa Pro Val Lys Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Leu Ser Val Xaa Leu Gly Val Pro Val Lys Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Leu Ser Val Xaa Leu Gly Ile Pro Val Lys Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
(B) LOCATION: 4..7
(D) OTHER INFORMATION: /label= Xaa
/note= "Xaa at position 4 is any amino acid but not a glutamic
acid residue. Xaa at position 7 is Val or Ile."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Leu Ser Xaa Xaa Leu Xaa Xaa Pro Xaa Xaa Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
 (B) LOCATION: 4
 (D) OTHER INFORMATION: /label= Xaa
 /note= "Xaa at position 4 is any amino acid except Glu."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
 (B) LOCATION: 2..5.
 (D) OTHER INFORMATION: /label= Xaa
 /note= "Xaa at position 2 is Ser or Ala, Xaa at Position 4 is
 any amino acid except Glu and Xaa at Position 5 is Leu or Ile."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
 (B) LOCATION: 4
 (D) OTHER INFORMATION: /label= Xaa
 /note= "Xaa at position 4 is any amino acid except Glu."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Leu Ser Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Glu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGAAGGGCG ATCGGTGCGG GCCTCTTCGC

30

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Arg Arg Xaa Xaa Lys Xaa Xaa Asn Tyr Xaa Xaa Xaa Tyr Gly
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Region
- (B) LOCATION: 3..6
- (D) OTHER INFORMATION: /label= Xaa

/note= "Xaa at position 3 is Gln or Gly. Xaa at position 4 is any amino acid except Glu. Xaa at position 6 is Ser or Ala."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Leu Ser Xaa Xaa Leu Xaa Ile Pro Tyr Glu Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
 (B) LOCATION: 4
 (D) OTHER INFORMATION: /label= Xaa
 /note= "Xaa at position 4 is any amino acid except Glu."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Leu Ser Gln Xaa Leu Ala Ile Pro Tyr Glu Glu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
 (B) LOCATION: 4..7
 (D) OTHER INFORMATION: /label= Xaa
 /note= "Xaa at position 4 is any amino acid except Glu. Xaa at position 7 is Val of Ile."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Leu Ser Val Xaa Leu Gly Xaa Pro Val Lys Glu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region
 (B) LOCATION: 4
 (D) OTHER INFORMATION: /label= Xaa
 /note= "Xaa at position 4 is any amino acid except Glu."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Leu Ser Val Xaa Leu Gly Val Pro Val Lys Glu
 1 5 10

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 11 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region

(B) LOCATION: 4

(D) OTHER INFORMATION: /label= Xaa

/note= "Xaa at position 4 is any amino acid except Glu."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Leu Ser Val Xaa Leu Gly Ile Pro Val Lys Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Region

(B) LOCATION: 4..7

(D) OTHER INFORMATION: /label= Xaa

/note= "Xaa at position 4 is any amino acid except Glu. Xaa at position 7 is Val or Ile."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Ser Gln Ile Xaa Leu Arg Xaa
1 5

Claims

1. A recombinant thermostable DNA polymerase which is characterized in that

a) in its native form said polymerase comprises the amino acid sequence LeuSerXaaXaaLeuXaaXaaProXaaXaaGlu (SEQ ID NO: 1), whereby "Xaa" at positions 3, 4, 6, 9, and 10 of said sequence are any amino acid residue, and "Xaa" at position 7 of said sequence is Val or Ile;

b) said "Xaa" at position 4 is mutated in comparison to said native sequence, except that "Xaa" at position 4 is not mutated to Glu; and

c) said thermostable DNA polymerase has a level of discrimination against incorporation of nucleotides labeled with fluorescein family dyes which is reduced in comparison to the native form of said polymerase.

2. The recombinant thermostable DNA polymerase of claim 1 wherein said nucleotide is a dideoxynucleotide and said level of discrimination is at least 3-fold lower than that of said native form of said polymerase.

3. The recombinant thermostable DNA polymerase of claim 2 wherein said level of discrimination is measured by determining the concentration of a dideoxynucleotide labeled with a fluorescein dye that is required for 50% inhibi-

tion of DNA synthesis

4. The recombinant thermostable DNA polymerase of claim 2 wherein said polymerase is from a thermophilic species selected from the group consisting of *Thermosipho africanus*, *Bacillus caldovenax*, and *Bacillus stearothermophilus*.
5. The recombinant thermostable DNA polymerase of claim 2 wherein said polymerase is from a *Thermus* species.
6. The recombinant thermostable DNA polymerase of claim 5 which is characterized in that
 - a) in its native form said polymerase comprises the amino acid sequence LeuSerXaaXaaLeuXaalleProTyr-GluGlu (SEQ ID NO: 2), whereby "Xaa" at position 3 is Gln or Gly, "Xaa" at position 4 is any amino acid, and "Xaa" at position 6 is Ser or Ala
 - b) said "Xaa" at position 4 is mutated in comparison to said native sequence, except that "Xaa" at position 4 is not mutated to Glu; and
 - c) said thermostable DNA polymerase has a level of discrimination against incorporation of nucleotides labeled with fluorescein family dyes which is reduced in comparison to the native form of said polymerase.
7. The recombinant thermostable DNA polymerase of claim 6 which is characterized in that
 - a) in its native form said polymerase comprises the amino acid sequence LeuSerGlnXaaLeuAlalleProTyr-GluGlu (SEQ ID NO: 3), whereby "Xaa" at position 4 is any amino acid
 - b) said "Xaa" at position 4 is mutated in comparison to said native sequence, except that "Xaa" at position 4 is not mutated to Glu; and
 - c) said thermostable DNA polymerase has a level of discrimination against incorporation of nucleotides labeled with fluorescein family dyes which is reduced in comparison to the native form of said polymerase.
8. The recombinant thermostable DNA polymerase of claim 7 which is characterized in that said "Xaa" at position 4 is mutated to Lys.
9. The recombinant thermostable DNA polymerase of claim 2 wherein said polymerase is from a *Thermotoga* species.
10. The recombinant thermostable DNA polymerase of claim 9 which is characterized in that
 - a) in its native form said polymerase comprises the amino acid sequence LeuSerValXaaLeuGlyXaaProVal-LysGlu (SEQ ID NO: 4), whereby "Xaa" at position 4 is any amino acid, preferably Arg, and "Xaa" at position 7 is Val or Ile.
 - b) said "Xaa" at position 4 is mutated in comparison to said native sequence, except that "Xaa" at position 4 is not mutated to Glu; and
 - c) said thermostable DNA polymerase has a level of discrimination against incorporation of nucleotides labeled with fluorescein family dyes which is reduced in comparison to the native form of said polymerase.
11. A nucleic acid sequence encoding a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10.
12. A vector comprising a nucleic acid sequence encoding a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10.
13. A host cell comprising a nucleic acid sequence encoding a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10.
14. A method for preparing a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10, said method comprises:
 - (a) culturing a host cell comprising a nucleic acid sequence encoding a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10 under conditions which promote the expression of the recombinant thermostable DNA polymerase; and

(b) isolating the recombinant thermostable DNA polymerase from the host cell or from the medium.

15. A recombinant thermostable DNA polymerase prepared by the method as claimed in claim 14.

16. A method of DNA sequencing which method comprises:

- a) providing a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10;
- b) providing a dye-terminator labeled with a negatively charged fluorescent dye; and
- c) performing a dye-terminator sequencing reaction.

17. The method of claim 16 wherein the recombinant thermostable DNA polymerase has a reduced level of discrimination against incorporation of nucleotides labeled with fluorescein family dyes and wherein the said nucleotide is a dideoxynucleotide and said level of discrimination is measured by determining the ratio of the concentration of a dideoxynucleotide labeled with a fluorescein dye required for 50% inhibition of DNA synthesis versus the concentration of an unlabeled dideoxynucleotide required for 50% inhibition.

18. The method of claim 17 wherein said ratio is 4 or less.

19. A method of producing labeled DNA which method comprises:

- a) providing a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10;
- b) providing a nucleotide labeled with a fluorescein family dye; and
- c) performing a DNA synthesis reaction.

20. A method of producing labeled primer extension products which method comprises:

- a) providing a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10;

- i) said polymerase comprises the amino acid sequence LeuSerValXaaLeuGlyXaaProValLysGlu (SEQ ID NO: 4), whereby "Xaa" at position 4 can be any amino acid except Glu, and "Xaa" at position 7 of this sequence is Val or Ile,

- ii) said polymerase has a reduced level of discrimination against incorporation of nucleotides labeled with fluorescein family dyes;

- iii) said polymerase also comprises the second amino acid sequence SQIXLR(V/I) (SEQ ID NO: 18) where "X" is any amino acid except E,

- iv) said polymerase has reduced discrimination against incorporation of ribonucleotides labeled with fluorescein family dyes;

- b) providing a ribonucleotide labeled with a fluorescein family dye, and

- c) performing a primer extension reaction.

21. The use of a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10 in a in vitro DNA synthesis application, such as DNA sequencing, synthesis of labeled DNA and the production of labeled primer extension products.

22. A kit for DNA sequencing which comprises a thermostable DNA polymerase as claimed in any one of claims 1 to 10 and a terminator labeled with negatively-charged fluorescent dye.

23. The kit of claim 22 wherein the said recombinant thermostable DNA polymerase has reduced discrimination against incorporation of nucleotides labeled with fluorescein family dyes and wherein said reduced level of discrimination is measured by determining the ratio of the concentration of ddNTP labeled with a fluorescein family dye required for 50% inhibition of DNA synthesis compared to that for an unlabeled ddNTP and said ratio is 4 or less.

24. The kit of claim 23 wherein said level of discrimination is at least 5-fold lower than that of said native form of said polymerase.

25. A kit for producing labeled DNA which comprises a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10 and a nucleotide labeled with a negatively-charged fluorescent dye.

26. A kit for producing labeled primer extension products which comprises a recombinant thermostable DNA polymerase as claimed in any one of claims 1 to 10 and a ribonucleotide labeled with a fluorescein family dye.

5

10

15

20

25

30

35


40

45

50

55

Fig. 1



THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 902 035 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
23.06.1999 Bulletin 1999/25

(51) Int. Cl.⁶: C07K 14/32, C12N 9/00,
C12N 15/11, C12N 15/31

(43) Date of publication A2:
17.03.1999 Bulletin 1999/11

(21) Application number: 98116786.9

(22) Date of filing: 05.09.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 11.09.1997 US 58525 P

(71) Applicant:
F. HOFFMANN-LA ROCHE AG
4070 Basel (CH)

(72) Inventors:
• Gelfand, David H.
Oakland, California 94611 (US)


• Kalman, Lisa Vivian
San Francisco, California 94131 (US)
• Myers, Thomas W.
Alameda, California (US)
• Reichert, Fred Lawrence
Oakland, California 94610 (US)
• Sigua, Christopher Lim
Antioch, California (US)

(74) Representative:
Wächter, Dieter Ernst, Dr. et al
F. Hoffmann-La Roche AG
Patent Department (PLP),
124 Grenzacherstrasse
4070 Basel (CH)

(54) Altered thermostable DNA polymerases for sequencing

(57) Modified thermostable DNA polymerases having enhanced efficiency for incorporating unconventional nucleotides such as those labeled with fluorescein family dyes are provided. Such modified thermostable DNA polymerases can be prepared by methods of the recombinant DNA technology. Recombinant thermostable DNA polymerases prepared in accordance with the present invention are advantageous in many in vitro DNA synthesis applications, such as DNA sequencing, synthesis of labeled DNA and the production of labeled primer extension products. The said polymerase enzymes are particularly useful in chain termination nucleic acid sequencing methods. Nucleic acids encoding the recombinant thermostable DNA polymerases of the present invention, as well as vectors and host cells comprising same are also provided. Kits comprising the recombinant thermostable DNA polymerases of the present invention are provided too. The polymerases and methods of the present invention provide significant cost and efficiency advantages for DNA sequencing.

Fig. 1



EP 0 902 035 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 98 11 6786

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.6)
P,A	EP 0 823 479 A (F. HOFFMANN-LA ROCHE AG) 11 February 1998 *see the whole patent*	1-26	C07K14/32 C12N9/00 C12N15/11 C12N15/31
X	EP 0 655 506 A (THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE) 31 May 1995 *see the whole patent*	1-26	
A	M.A. REEVE ET AL.: "A novel thermostable polymerase for DNA sequencing" NATURE, vol. 376, 1995, pages 796-797, XP000606193 *see the whole article*	1-26	
A	H. VOSS ET AL.: "Automated cycle sequencing with Taqenase: Protocols for internal labeling, dye primer and doublex simultaneous sequencing" BIOTECHNIQUES, vol. 23, no. 28, 1977, pages 312-318, XP000698417 *see the whole article*	1-26	
			TECHNICAL FIELDS SEARCHED (Int.CI.6)
			C12N C07K
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
MUNICH		27 April 1999	Marie, A
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 11 6786

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

27-04-1999

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 823479	A	11-02-1998	AU 3319797 A	12-02-1998
			BR 9704260 A	15-09-1998
			CA 2210951 A	06-02-1998
			CZ 9702299 A	17-06-1998
			JP 10066588 A	10-03-1998
			NO 973595 A	09-02-1998
			PL 321478 A	16-02-1998

EP 655506	A	31-05-1995	US 5614365 A	25-03-1997
			AT 143057 T	15-10-1996
			AU 4193396 A	06-05-1996
			CA 2201885 A	25-04-1996
			CN 1170439 A	14-01-1998
			DE 29513622 U	19-10-1995
			DE 29513639 U	19-10-1995
			DE 69400567 D	24-10-1996
			DE 69400567 T	06-02-1997
			DE 655506 T	28-09-1995
			DK 655506 T	10-03-1997
			EP 0727496 A	21-08-1996
			ES 2072238 T	16-07-1995
			FI 971611 A	13-06-1997
			GR 95300040 T	31-07-1995
			HU 77037 A	02-03-1998
			JP 2691149 B	17-12-1997
			JP 8205874 A	13-08-1996
			WO 9612042 A	25-04-1997
			ZA 9508761 A	13-05-1996

THIS PAGE BLANK (USPTO)